

Paolo Calabresi

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7337009/publications.pdf>

Version: 2024-02-01

602
papers

36,936
citations

2440

100
h-index

7234

158
g-index

607
all docs

607
docs citations

607
times ranked

32347
citing authors

#	ARTICLE	IF	CITATIONS
1	Clinical features and outcome of patients with autoimmune cerebellar ataxia evaluated with the Scale for the Assessment and Rating of Ataxia. <i>European Journal of Neurology</i> , 2022, 29, 564-572.	1.7	11
2	Remission of functional motor symptoms following esketamine administration in a patient with treatment-resistant depression: a single-case report. <i>International Clinical Psychopharmacology</i> , 2022, 37, 21-24.	0.9	5
3	Mechanical thrombectomy in acute ischemic stroke due to large vessel occlusion in the anterior circulation and low baseline National Institute of Health Stroke Scale score: a multicenter retrospective matched analysis. <i>Neurological Sciences</i> , 2022, 43, 3105-3112.	0.9	15
4	Cognitive Decline Risk Stratification in People with Late-Onset Epilepsy of Unknown Etiology: An Electroencephalographic Connectivity and Graph Theory Pilot Study. <i>Journal of Alzheimer's Disease</i> , 2022, 88, 893-901.	1.2	6
5	A real-time integrated framework to support clinical decision making for covid-19 patients. <i>Computer Methods and Programs in Biomedicine</i> , 2022, 217, 106655.	2.6	8
6	Plasticity, genetics, and epigenetics in l-dopa-induced dyskinesias. <i>Handbook of Clinical Neurology / Edited By P J Vinken and G W Bruyn</i> , 2022, 184, 167-184.	1.0	4
7	Alpha-synuclein and cortico-striatal plasticity in animal models of Parkinson disease. <i>Handbook of Clinical Neurology / Edited By P J Vinken and G W Bruyn</i> , 2022, 184, 153-166.	1.0	4
8	Clinical and genetic characteristics of late-onset Huntington's disease in a large European cohort. <i>European Journal of Neurology</i> , 2022, 29, 1940-1951.	1.7	3
9	Striatal glutamatergic hyperactivity in Parkinson's disease. <i>Neurobiology of Disease</i> , 2022, 168, 105697.	2.1	26
10	Immunological findings in patients with migraine and other primary headaches: a narrative review. <i>Clinical and Experimental Immunology</i> , 2022, 207, 11-26.	1.1	18
11	Autonomic dysfunction in non-critically ill COVID-19 patients during the acute phase of disease: an observational, cross-sectional study. <i>Neurological Sciences</i> , 2022, 43, 4635-4643.	0.9	12
12	STN-DBS does not increase the risk of sialorrhea in patients with advanced Parkinson's disease. <i>Npj Parkinson's Disease</i> , 2022, 8, .	2.5	1
13	Autonomic Dysfunction during Acute SARS-CoV-2 Infection: A Systematic Review. <i>Journal of Clinical Medicine</i> , 2022, 11, 3883.	1.0	18
14	Levetiracetam-responsive belly dancer's syndrome in a case of progressive supranuclear palsy. <i>Acta Neurologica Belgica</i> , 2021, 121, 765-766.	0.5	2
15	Reperfusion strategies in stroke due to isolated cervical internal carotid artery occlusion: systematic review and treatment comparison. <i>Neurological Sciences</i> , 2021, 42, 2301-2308.	0.9	11
16	Changes of olfactory tract in Parkinson's disease: a DTI tractography study. <i>Neuroradiology</i> , 2021, 63, 235-242.	1.1	13
17	Effect of the COVID-19 pandemic and the lockdown measures on the local stroke network. <i>Neurological Sciences</i> , 2021, 42, 1237-1245.	0.9	10
18	Mechanical thrombectomy in patients with stroke due to large vessel occlusion in the anterior circulation and low scale score. <i>Journal of Integrative Neuroscience</i> , 2021, 20, 645.	0.8	2

#	ARTICLE	IF	CITATIONS
19	Developmental impaired Akt signaling in the Shank1 and Shank3 double knock-out mice. <i>Molecular Psychiatry</i> , 2021, 26, 1928-1944.	4.1	26
20	Role of Favorable Perfusion Imaging in Predicting the Outcome of Patients with Acute Ischemic Stroke due to Large Vessel Occlusion Undergoing Effective Thrombectomy: A Single-Center Study. <i>Cerebrovascular Diseases Extra</i> , 2021, 11, 1-8.	0.5	2
21	Long-Term Shaping of Corticostriatal Synaptic Activity by Acute Fasting. <i>International Journal of Molecular Sciences</i> , 2021, 22, 1916.	1.8	2
22	High performance liquid chromatography determination of l-glutamate, l-glutamine and glycine content in brain, cerebrospinal fluid and blood serum of patients affected by Alzheimer's disease. <i>Amino Acids</i> , 2021, 53, 435-449.	1.2	14
23	COVID-19 and stroke: from the cases to the causes. <i>Reviews in the Neurosciences</i> , 2021, 32, 659-669.	1.4	6
24	Global impact of COVID-19 on stroke care. <i>International Journal of Stroke</i> , 2021, 16, 573-584.	2.9	104
25	Extradural Motor Cortex Stimulation in Parkinson's Disease: Long-Term Clinical Outcome. <i>Brain Sciences</i> , 2021, 11, 416.	1.1	6
26	Neuro-Immune Cross-Talk in the Striatum: From Basal Ganglia Physiology to Circuit Dysfunction. <i>Frontiers in Immunology</i> , 2021, 12, 644294.	2.2	16
27	Defining the disease course of TNF blockers-associated Multiple Sclerosis. <i>Journal of Neuroimmunology</i> , 2021, 353, 577525.	1.1	4
28	Personalized Clinical Phenotyping through Systems Medicine and Artificial Intelligence. <i>Journal of Personalized Medicine</i> , 2021, 11, 265.	1.1	14
29	Tracing Neurological Diseases in the Presymptomatic Phase: Insights From Neurofilament Light Chain. <i>Frontiers in Neuroscience</i> , 2021, 15, 672954.	1.4	19
30	Small-expanded allele spinocerebellar ataxia 17: imaging and phenotypic variability. <i>Neurological Sciences</i> , 2021, 42, 4309-4315.	0.9	5
31	Amyloid- β : a potential link between epilepsy and cognitive decline. <i>Nature Reviews Neurology</i> , 2021, 17, 469-485.	4.9	60
32	Dopamine-dependent early synaptic and motor dysfunctions induced by α -synuclein in the nigrostriatal circuit. <i>Brain</i> , 2021, 144, 3477-3491.	3.7	49
33	Renal Involvement in Hereditary Transthyretin Amyloidosis: An Italian Single-Centre Experience. <i>Brain Sciences</i> , 2021, 11, 980.	1.1	18
34	CACNA1A-p.Thr501Met mutation associated with familial hemiplegic migraine: a family report. <i>Journal of Headache and Pain</i> , 2021, 22, 85.	2.5	3
35	Transcranial Magnetic Stimulation Exerts "Rejuvenation" Effects on Corticostriatal Synapses after Partial Dopamine Depletion. <i>Movement Disorders</i> , 2021, 36, 2254-2263.	2.2	10
36	The contribution of the Italian residents in neurology to the COVID-19 crisis: admirable generosity but neurological training remains their priority. <i>Neurological Sciences</i> , 2021, 42, 4425-4431.	0.9	1

#	ARTICLE	IF	CITATIONS
37	Ixekizumab exposure associated with myelitis: A case report and a literature review. <i>Journal of Neuroimmunology</i> , 2021, 361, 577726.	1.1	3
38	Serotonin drives striatal synaptic plasticity in a sex-related manner. <i>Neurobiology of Disease</i> , 2021, 158, 105448.	2.1	3
39	CalDAG-GEFI mediates striatal cholinergic modulation of dendritic excitability, synaptic plasticity and psychomotor behaviors. <i>Neurobiology of Disease</i> , 2021, 158, 105473.	2.1	8
40	CACNA1A-P.THR501MET mutation associated with familial hemiplegic migraine: A family report. <i>Journal of the Neurological Sciences</i> , 2021, 429, 119276.	0.3	0
41	Delirium in acute stroke: A single centre, prospective, cross-sectional, cohort study. <i>Journal of the Neurological Sciences</i> , 2021, 429, 117655.	0.3	1
42	CSF CXCL13 and chitinase 3-like-1 concentrations predict disease course in relapsing multiple sclerosis. <i>Journal of the Neurological Sciences</i> , 2021, 429, 118114.	0.3	0
43	Cognitive decline in late-onset epilepsy of undefined etiology: A longitudinal cohort study. <i>Journal of the Neurological Sciences</i> , 2021, 429, 117709.	0.3	0
44	Interleukin-17 axis in the modulation of cortical and subcortical synaptic plasticity across disease stages in experimental multiple sclerosis. <i>Journal of the Neurological Sciences</i> , 2021, 429, 117746.	0.3	0
45	Effects of uremic toxins on hippocampal synaptic transmission: implication for neurodegeneration in chronic kidney disease. <i>Cell Death Discovery</i> , 2021, 7, 295.	2.0	8
46	Theory of mind: A clue to functional movement disorders diagnosis. <i>Journal of the Neurological Sciences</i> , 2021, 429, 117681.	0.3	0
47	Lexical-semantic system disruption correlation with Alzheimer's pathophysiological processes. <i>Journal of the Neurological Sciences</i> , 2021, 429, 119011.	0.3	0
48	A machine-learning parsimonious multivariable predictive model of mortality risk in patients with Covid-19. <i>Scientific Reports</i> , 2021, 11, 21136.	1.6	14
49	Cognitive decline risk stratification in people with late-onset epilepsy of unknown etiology: An electroencephalographic connectivity and graph theory pilot study. <i>Journal of the Neurological Sciences</i> , 2021, 429, 117686.	0.3	1
50	Motor and neurophysiological features of sleep in Huntington disease: A single-center, prospective, cross-sectional, cohort study. <i>Journal of the Neurological Sciences</i> , 2021, 429, 117833.	0.3	0
51	Headache and immunological/autoimmune disorders: a comprehensive review of available epidemiological evidence with insights on potential underlying mechanisms. <i>Journal of Neuroinflammation</i> , 2021, 18, 259.	3.1	20
52	Connectivity modulations induced by reach&grasp movements: a multidimensional approach. <i>Scientific Reports</i> , 2021, 11, 23097.	1.6	4
53	Incidence and Antiseizure Medications of Post-stroke Epilepsy in Umbria: A Population-Based Study Using Healthcare Administrative Databases. <i>Frontiers in Neurology</i> , 2021, 12, 800524.	1.1	3
54	Interleukin-17 affects synaptic plasticity and cognition in an experimental model of multiple sclerosis. <i>Cell Reports</i> , 2021, 37, 110094.	2.9	38

#	ARTICLE	IF	CITATIONS
55	Instrumental Evaluation of COVID-19 Related Dysautonomia in Non-Critically-Ill Patients: An Observational, Cross-Sectional Study. <i>Journal of Clinical Medicine</i> , 2021, 10, 5861.	1.0	14
56	Cerebrospinal fluid free light chains compared to oligoclonal bands as biomarkers in multiple sclerosis. <i>Journal of Neuroimmunology</i> , 2020, 339, 577108.	1.1	31
57	Assessment of neurological manifestations in hospitalized patients with COVID-19. <i>European Journal of Neurology</i> , 2020, 27, 2322-2328.	1.7	36
58	COVID-19 Pandemic and Psychiatric Symptoms: The Impact on Parkinson's Disease in the Elderly. <i>Frontiers in Psychiatry</i> , 2020, 11, 581144.	1.3	37
59	Giacomo Balla: A Painter in the Context of Neuroscience. <i>Neuroscientist</i> , 2020, , 107385842097638.	2.6	0
60	From Synaptic Dysfunction to Neuroprotective Strategies in Genetic Parkinson's Disease: Lessons From LRRK2. <i>Frontiers in Cellular Neuroscience</i> , 2020, 14, 158.	1.8	15
61	Rapamycin, by Inhibiting mTORC1 Signaling, Prevents the Loss of Striatal Bidirectional Synaptic Plasticity in a Rat Model of L-DOPA-Induced Dyskinesia. <i>Frontiers in Aging Neuroscience</i> , 2020, 12, 230.	1.7	18
62	Cerebrospinal fluid and serum d-serine concentrations are unaltered across the whole clinical spectrum of Alzheimer's disease. <i>Biochimica Et Biophysica Acta - Proteins and Proteomics</i> , 2020, 1868, 140537.	1.1	19
63	Extradural Motor Cortex Stimulation might improve episodic and working memory in patients with Parkinson's disease. <i>Npj Parkinson's Disease</i> , 2020, 6, 26.	2.5	5
64	Stroke and COVID19: Not only a large-vessel disease. <i>Journal of Stroke and Cerebrovascular Diseases</i> , 2020, 29, 105074.	0.7	13
65	Continuous Dopaminergic Stimulation as a Treatment for Parkinson's Disease: Current Status and Future Opportunities. <i>Movement Disorders</i> , 2020, 35, 1731-1744.	2.2	47
66	Maternal stress programs accelerated aging of the basal ganglia motor system in offspring. <i>Neurobiology of Stress</i> , 2020, 13, 100265.	1.9	3
67	A proof-of-concept study on CGRP plasma levels of migraineurs during a 6-month treatment with ERENUMAB. <i>Journal of Headache and Pain</i> , 2020, 21, 124.	2.5	7
68	Neurology and the COVID-19 emergency. <i>Neurological Sciences</i> , 2020, 41, 1343-1344.	0.9	8
69	Stroke integrated care pathway during COVID-19 pandemic. <i>Neurological Sciences</i> , 2020, 41, 1673-1675.	0.9	8
70	Effects of safinamide on the glutamatergic striatal network in experimental Parkinson's disease. <i>Neuropharmacology</i> , 2020, 170, 108024.	2.0	8
71	Host and Microbial Tryptophan Metabolic Profiling in Multiple Sclerosis. <i>Frontiers in Immunology</i> , 2020, 11, 157.	2.2	35
72	An Italian Neurology Outpatient Clinic Facing SARS-CoV-2 Pandemic: Data From 2,167 Patients. <i>Frontiers in Neurology</i> , 2020, 11, 564.	1.1	30

#	ARTICLE	IF	CITATIONS
73	Effect of lockdown on the management of ischemic stroke: an Italian experience from a COVID hospital. <i>Neurological Sciences</i> , 2020, 41, 2309-2313.	0.9	39
74	Positive allosteric modulation of indoleamine 2,3-dioxygenase 1 restrains neuroinflammation. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2020, 117, 3848-3857.	3.3	58
75	Time trends, frequency, characteristics and prognosis of short-duration transient global amnesia. <i>European Journal of Neurology</i> , 2020, 27, 887-893.	1.7	24
76	Dural arteriovenous fistulas and headache features: an observational study. <i>Journal of Headache and Pain</i> , 2020, 21, 6.	2.5	13
77	Impulse Control Disorders and Levodopa-Induced Dyskinesias in Parkinson's Disease: Pulsatile versus Continuous Dopaminergic Stimulation. <i>Journal of Parkinson's Disease</i> , 2020, 10, 927-934.	1.5	5
78	Focal status epilepticus as unique clinical feature of COVID-19: A case report. <i>Seizure: the Journal of the British Epilepsy Association</i> , 2020, 78, 109-112.	0.9	152
79	Does SARS-CoV-2 invade the brain? Translational lessons from animal models. <i>European Journal of Neurology</i> , 2020, 27, 1764-1773.	1.7	214
80	Aspirin or anticoagulation after cryptogenic stroke with patent foramen ovale: systematic review and meta-analysis of randomized controlled trials. <i>Neurological Sciences</i> , 2020, 41, 2819-2824.	0.9	10
81	Low doses of Perampanel protect striatal and hippocampal neurons against in vitro ischemia by reversing the ischemia-induced alteration of AMPA receptor subunit composition. <i>Neurobiology of Disease</i> , 2020, 140, 104848.	2.1	19
82	Unprotected stroke management in an undiagnosed case of Severe Acute Respiratory Syndrome Coronavirus 2 infection. <i>Journal of Stroke and Cerebrovascular Diseases</i> , 2020, 29, 104981.	0.7	15
83	Gastrointestinal Manifestations in Hereditary Transthyretin Amyloidosis: a Single-Centre Experience. <i>Journal of Gastrointestinal and Liver Diseases</i> , 2020, 29, 339-343.	0.5	10
84	Effects of COVID-19 Lockdown on Movement Disorders Patients With Deep Brain Stimulation: A Multicenter Survey. <i>Frontiers in Neurology</i> , 2020, 11, 616550.	1.1	18
85	Characterization of Brain Lysosomal Activities in GBA-Related and Sporadic Parkinson's Disease and Dementia with Lewy Bodies. <i>Molecular Neurobiology</i> , 2019, 56, 1344-1355.	1.9	97
86	Cerebrospinal fluid neurofilament light chain predicts disease activity after the first demyelinating event suggestive of multiple sclerosis. <i>Multiple Sclerosis and Related Disorders</i> , 2019, 35, 228-232.	0.9	20
87	Long-Term Risk of Stroke After Transient Global Amnesia in Two Prospective Cohorts. <i>Stroke</i> , 2019, 50, 2555-2557.	1.0	20
88	Hippocampal epileptogenesis in autoimmune encephalitis. <i>Annals of Clinical and Translational Neurology</i> , 2019, 6, 2261-2269.	1.7	20
89	Corticostriatal synaptic plasticity alterations in the R6/1 transgenic mouse model of Huntington's disease. <i>Journal of Neuroscience Research</i> , 2019, 97, 1655-1664.	1.3	10
90	Dystonia and levodopa-induced dyskinesias in Parkinson's disease: Is there a connection?. <i>Neurobiology of Disease</i> , 2019, 132, 104579.	2.1	27

#	ARTICLE	IF	CITATIONS
91	Current and emerging evidence-based treatment options in chronic migraine: a narrative review. <i>Journal of Headache and Pain</i> , 2019, 20, 92.	2.5	116
92	Blunting neuroinflammation with resolvin D1 prevents early pathology in a rat model of Parkinson's disease. <i>Nature Communications</i> , 2019, 10, 3945.	5.8	127
93	The levels of the NMDA receptor co-agonist D-serine are reduced in the substantia nigra of MPTP-lesioned macaques and in the cerebrospinal fluid of Parkinson's disease patients. <i>Scientific Reports</i> , 2019, 9, 8898.	1.6	31
94	Synaptic vesicle protein 2A tumoral expression predicts levetiracetam adverse events. <i>Journal of Neurology</i> , 2019, 266, 2273-2276.	1.8	4
95	Cerebrospinal fluid neurofilament light chain tracks cognitive impairment in multiple sclerosis. <i>Journal of Neurology</i> , 2019, 266, 2157-2163.	1.8	41
96	The Italian version of Cognitive Function Instrument (CFI) for tracking changes in healthy elderly: results at 1-year follow-up. <i>Neurological Sciences</i> , 2019, 40, 2147-2153.	0.9	8
97	Validation of the Hemifacial Spasm Grading Scale: a clinical tool for hemifacial spasm. <i>Neurological Sciences</i> , 2019, 40, 1887-1892.	0.9	9
98	Substantia nigra hyperechogenicity in essential tremor and Parkinson's disease: a longitudinal study. <i>European Journal of Neurology</i> , 2019, 26, 1370-1376.	1.7	12
99	Dopamine drives binge-like consumption of a palatable food in experimental Parkinsonism. <i>Movement Disorders</i> , 2019, 34, 821-831.	2.2	11
100	Incidence and prevalence of Parkinson's disease in the Italian region of Umbria: a population-based study using healthcare administrative databases. <i>Neurological Sciences</i> , 2019, 40, 1709-1712.	0.9	14
101	Epilepsy, headache, and chronic pain. , 2019, , 187-205.		0
102	Quantal Release of Dopamine and Action Potential Firing Detected in Midbrain Neurons by Multifunctional Diamond-Based Microarrays. <i>Frontiers in Neuroscience</i> , 2019, 13, 288.	1.4	34
103	A nurse-led model increases quality of care in Parkinson disease. <i>Neurology</i> , 2019, 92, 739-740.	1.5	6
104	Neurofilament light chain as a biomarker in neurological disorders. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2019, 90, 870-881.	0.9	623
105	CSF and blood biomarkers for Parkinson's disease. <i>Lancet Neurology</i> , The, 2019, 18, 573-586.	4.9	393
106	T2*-weighted MRI values correlate with motor and cognitive dysfunction in Parkinson's disease. <i>Neurobiology of Aging</i> , 2019, 80, 91-98.	1.5	16
107	Alpha-synuclein targets GluN2A NMDA receptor subunit causing striatal synaptic dysfunction and visuospatial memory alteration. <i>Brain</i> , 2019, 142, 1365-1385.	3.7	82
108	Differential effect of FHM2 mutation on synaptic plasticity in distinct hippocampal regions. <i>Cephalalgia</i> , 2019, 39, 1333-1338.	1.8	8

#	ARTICLE	IF	CITATIONS
109	Selective inhibition of mitochondrial sodium-calcium exchanger protects striatal neurons from β -synuclein plus rotenone induced toxicity. <i>Cell Death and Disease</i> , 2019, 10, 80.	2.7	17
110	The Madwoman: a portrait of a choreic woman?. <i>Lancet Neurology</i> , The, 2019, 18, 233.	4.9	1
111	Striatal spreading depolarization: Possible implication in levodopa-induced dyskinesia-like behavior. <i>Movement Disorders</i> , 2019, 34, 832-844.	2.2	6
112	Cognitive performances in patients affected by late-onset epilepsy with unknown etiology: A 12-month follow-up study. <i>Epilepsy and Behavior</i> , 2019, 101, 106592.	0.9	21
113	Bidirectional Synaptic Plasticity Is Driven by Sex Neurosteroids Targeting Estrogen and Androgen Receptors in Hippocampal CA1 Pyramidal Neurons. <i>Frontiers in Cellular Neuroscience</i> , 2019, 13, 534.	1.8	20
114	Alzheimer's disease and late-onset epilepsy of unknown origin: two faces of beta amyloid pathology. <i>Neurobiology of Aging</i> , 2019, 73, 61-67.	1.5	75
115	An evolving redefinition of autoimmune encephalitis. <i>Autoimmunity Reviews</i> , 2019, 18, 155-163.	2.5	44
116	Teaching Images in Headache: Thrombosis of Posterior Communicating Artery Aneurysm. <i>Headache</i> , 2019, 59, 630-631.	1.8	0
117	NMDA receptor GluN2D subunit participates to levodopa-induced dyskinesia pathophysiology. <i>Neurobiology of Disease</i> , 2019, 121, 338-349.	2.1	24
118	Valproic Acid and Epilepsy: From Molecular Mechanisms to Clinical Evidences. <i>Current Neuropharmacology</i> , 2019, 17, 926-946.	1.4	190
119	Synaptic plasticity and levodopa-induced dyskinesia: electrophysiological and structural abnormalities. <i>Journal of Neural Transmission</i> , 2018, 125, 1263-1271.	1.4	39
120	Subclinical vestibular dysfunction in migraineurs without vertigo: A Clinical study. <i>Acta Neurologica Scandinavica</i> , 2018, 138, 270-277.	1.0	11
121	Early management of patients with medication-overuse headache: results from a multicentre clinical study. <i>European Journal of Neurology</i> , 2018, 25, 1027-1033.	1.7	7
122	Dopamine D2 receptor-mediated neuroprotection in a G2019S Lrrk2 genetic model of Parkinson's disease. <i>Cell Death and Disease</i> , 2018, 9, 204.	2.7	35
123	Treatment of multiple sclerosis relapses with high-dose methylprednisolone reduces the evolution of contrast-enhancing lesions into persistent black holes. <i>Journal of Neurology</i> , 2018, 265, 522-529.	1.8	5
124	Microglial activation and the nitric oxide/cGMP/PKG pathway underlie enhanced neuronal vulnerability to mitochondrial dysfunction in experimental multiple sclerosis. <i>Neurobiology of Disease</i> , 2018, 113, 97-108.	2.1	27
125	Motor learning and metaplasticity in striatal neurons: relevance for Parkinson's disease. <i>Brain</i> , 2018, 141, 505-520.	3.7	62
126	A new enzyme-linked immunosorbent assay for neurofilament light in cerebrospinal fluid: analytical validation and clinical evaluation. <i>Alzheimer's Research and Therapy</i> , 2018, 10, 8.	3.0	111

#	ARTICLE	IF	CITATIONS
127	Lacosamide protects striatal and hippocampal neurons from inÂvitro ischemia without altering physiological synaptic plasticity. <i>Neuropharmacology</i> , 2018, 135, 424-430.	2.0	13
128	Liverpool Adverse Events Profile: Italian validation and predictive value for dropout from antiepileptic treatment in people with epilepsy. <i>Epilepsy and Behavior</i> , 2018, 81, 111-114.	0.9	10
129	Evidence of practice effect in CANTAB spatial working memory test in a cohort of patients with mild cognitive impairment. <i>Applied Neuropsychology Adult</i> , 2018, 25, 237-248.	0.7	34
130	Epilepsy in hemiplegic migraine: Genetic mutations and clinical implications. <i>Cephalalgia</i> , 2018, 38, 361-373.	1.8	36
131	Antiepileptic drugs in migraine and epilepsy: Who is at increased risk of adverse events?. <i>Cephalalgia</i> , 2018, 38, 274-282.	1.8	19
132	The Italian version of cognitive function instrument (CFI): reliability and validity in a cohort of healthy elderly. <i>Neurological Sciences</i> , 2018, 39, 111-118.	0.9	16
133	Motor complications in Parkinson's disease: Striatal molecular and electrophysiological mechanisms of dyskinesias. <i>Movement Disorders</i> , 2018, 33, 867-876.	2.2	82
134	Risk factors of levodopa-induced dyskinesia in Parkinsonâ€™s disease: results from the PPMI cohort. <i>Npj Parkinson's Disease</i> , 2018, 4, 33.	2.5	61
135	Levodopa in Parkinsonâ€™s Disease: Current Status and Future Developments. <i>Current Neuropharmacology</i> , 2018, 16, 1239-1252.	1.4	156
136	Drug-induced Creutzfeldt-Jakob disease-like syndrome: early CSF analysis as useful tool for differential diagnosis. <i>BMJ Case Reports</i> , 2018, 11, e224314.	0.2	3
137	Levodopaâ€™induced dyskinesia in Parkinson disease: Current and evolving concepts. <i>Annals of Neurology</i> , 2018, 84, 797-811.	2.8	225
138	2017 revisions of McDonald criteria shorten the time to diagnosis of multiple sclerosis in clinically isolated syndromes. <i>Journal of Neurology</i> , 2018, 265, 2684-2687.	1.8	35
139	Multiple sclerosis and cognition: synaptic failure and network dysfunction. <i>Nature Reviews Neuroscience</i> , 2018, 19, 599-609.	4.9	151
140	Levodopa-responsive breathing discomfort in Parkinsonâ€™s disease patients. <i>Journal of Neural Transmission</i> , 2018, 125, 1033-1036.	1.4	10
141	Selective basal ganglia vulnerability to energy deprivation: Experimental and clinical evidences. <i>Progress in Neurobiology</i> , 2018, 169, 55-75.	2.8	30
142	Alpha-Synuclein: From Early Synaptic Dysfunction to Neurodegeneration. <i>Frontiers in Neurology</i> , 2018, 9, 295.	1.1	138
143	Late-Onset N-Acetylglutamate Synthase Deficiency: Report of a Paradigmatic Adult Case Presenting with Headaches and Review of the Literature. <i>International Journal of Molecular Sciences</i> , 2018, 19, 345.	1.8	7
144	Late onset epilepsy and Alzheimerâ€™s disease: exploring the dual pathogenic role of amyloid-Î². <i>Brain</i> , 2018, 141, e60-e60.	3.7	12

#	ARTICLE	IF	CITATIONS
145	Dopamine D2 receptor activation potently inhibits striatal glutamatergic transmission in a G2019S LRRK2 genetic model of Parkinson's disease. <i>Neurobiology of Disease</i> , 2018, 118, 1-8.	2.1	22
146	Pharmacological enhancement of mGlu5 receptors rescues behavioral deficits in SHANK3 knock-out mice. <i>Molecular Psychiatry</i> , 2017, 22, 689-702.	4.1	134
147	Increased levels of CSF total but not oligomeric or phosphorylated forms of alpha-synuclein in patients diagnosed with probable Alzheimer's disease. <i>Scientific Reports</i> , 2017, 7, 40263.	1.6	51
148	Intermittent theta-burst stimulation rescues dopamine-dependent corticostriatal synaptic plasticity and motor behavior in experimental parkinsonism: Possible role of glial activity. <i>Movement Disorders</i> , 2017, 32, 1035-1046.	2.2	38
149	Homer1b/c clustering is impaired in Phelan-McDermid Syndrome iPSCs derived neurons. <i>Molecular Psychiatry</i> , 2017, 22, 637-637.	4.1	4
150	Switching on the lights of dyskinesia: Perspectives and limits of the optogenetic approaches. <i>Movement Disorders</i> , 2017, 32, 485-486.	2.2	5
151	Environmental Enrichment Repairs Structural and Functional Plasticity in the Hippocampus. , 2017, , 55-77.		1
152	Movement disorders in 2016: from genes to phenotypes. <i>Lancet Neurology</i> , The, 2017, 16, 9-10.	4.9	4
153	Cerebrospinal fluid Î²-galactosidase activity is reduced in parkinson's disease patients. <i>Movement Disorders</i> , 2017, 32, 1423-1431.	2.2	132
154	Visual pathway involvement in multiple sclerosis: Look straight in the eyes. <i>Multiple Sclerosis and Related Disorders</i> , 2017, 17, 217-219.	0.9	5
155	Rabphilin 3A: A novel target for the treatment of levodopa-induced dyskinesias. <i>Neurobiology of Disease</i> , 2017, 108, 54-64.	2.1	40
156	Past, present, and future of Parkinson's disease: A special essay on the 200th Anniversary of the Shaking Palsy. <i>Movement Disorders</i> , 2017, 32, 1264-1310.	2.2	608
157	Diagnostic utility of cerebrospinal fluid Î²-synuclein in Parkinson's disease: A systematic review and meta-analysis. <i>Movement Disorders</i> , 2017, 32, 1389-1400.	2.2	157
158	Neuropsychiatric adverse events of antiepileptic drugs in brain tumour-related epilepsy: an Italian multicentre prospective observational study. <i>European Journal of Neurology</i> , 2017, 24, 1283-1289.	1.7	30
159	Clinical features and outcome of 6 new patients carrying de novo <i>KCNB1</i> gene mutations. <i>Neurology: Genetics</i> , 2017, 3, e206.	0.9	53
160	Cerebrospinal fluid biomarkers for the diagnosis and prognosis of Parkinson's disease: protocol for a systematic review and individual participant data meta-analysis. <i>BMJ Open</i> , 2017, 7, e018177.	0.8	4
161	Hippocampal neuroplasticity and inflammation: relevance for multiple sclerosis. <i>Multiple Sclerosis and Demyelinating Disorders</i> , 2017, 2, .	1.1	19
162	High risk of early conversion to multiple sclerosis in clinically isolated syndromes with dissemination in space at baseline. <i>Journal of the Neurological Sciences</i> , 2017, 379, 236-240.	0.3	12

#	ARTICLE	IF	CITATIONS
163	Different synaptic stimulation patterns influence the local androgenic and estrogenic neurosteroid availability triggering hippocampal synaptic plasticity in the male rat. <i>European Journal of Neuroscience</i> , 2017, 45, 499-509.	1.2	10
164	Stopping Onabotulinum Treatment after the First Two Cycles Might Not Be Justified: Results of a Real-life Monocentric Prospective Study in Chronic Migraine. <i>Frontiers in Neurology</i> , 2017, 8, 655.	1.1	19
165	Differential role of CSF fatty acid binding protein 3, β -synuclein, and Alzheimer's disease core biomarkers in Lewy body disorders and Alzheimer's dementia. <i>Alzheimer's Research and Therapy</i> , 2017, 9, 52.	3.0	101
166	Decreased Rhes mRNA levels in the brain of patients with Parkinson's disease and MPTP-treated macaques. <i>PLoS ONE</i> , 2017, 12, e0181677.	1.1	12
167	Morning akinesia in Parkinson's disease: challenges and solutions. <i>Journal of Parkinsonism and Restless Legs Syndrome</i> , 2016, , 57.	0.8	1
168	Regulation of Corticostriatal Synaptic Plasticity in Physiological and Pathological Conditions. <i>Handbook of Behavioral Neuroscience</i> , 2016, 24, 459-476.	0.7	1
169	Biomarkers in Parkinson's disease: From pathophysiology to early diagnosis. <i>Movement Disorders</i> , 2016, 31, 769-770.	2.2	4
170	Early synaptic dysfunction in Parkinson's disease: Insights from animal models. <i>Movement Disorders</i> , 2016, 31, 802-813.	2.2	127
171	Diagnostic utility of CSF β -synuclein species in Parkinson's disease: protocol for a systematic review and meta-analysis. <i>BMJ Open</i> , 2016, 6, e011113.	0.8	10
172	Performance Evaluation of an Automated ELISA System for Alzheimer's Disease Detection in Clinical Routine. <i>Journal of Alzheimer's Disease</i> , 2016, 54, 55-67.	1.2	27
173	Multiple sclerosis and chronic progressive external ophthalmoplegia associated with a large scale mitochondrial DNA single deletion. <i>Journal of Neurology</i> , 2016, 263, 1449-1451.	1.8	2
174	Epilepsy, amyloid- β , and D1 dopamine receptors: a possible pathogenetic link?. <i>Neurobiology of Aging</i> , 2016, 48, 161-171.	1.5	71
175	Psychopathological comorbidities in medication-overuse headache: a multicentre clinical study. <i>European Journal of Neurology</i> , 2016, 23, 85-91.	1.7	36
176	Longitudinal changes in CSF alpha-synuclein species reflect Parkinson's disease progression. <i>Movement Disorders</i> , 2016, 31, 1535-1542.	2.2	120
177	Extracranial Venous Drainage Pattern in Multiple Sclerosis and Healthy Controls: Application of the 2011 Diagnostic Criteria for Chronic Cerebrospinal Venous Insufficiency. <i>European Neurology</i> , 2016, 76, 62-68.	0.6	4
178	Persistent activation of microglia and NADPH oxidase drive hippocampal dysfunction in experimental multiple sclerosis. <i>Scientific Reports</i> , 2016, 6, 20926.	1.6	68
179	The Small GTP-binding protein Rhes influences Nigrostriatal-dependent Motor Behavior during Aging. <i>Movement Disorders</i> , 2016, 31, 583-589.	2.2	14
180	Lysosomal Dysfunction and β -Synuclein Aggregation in Parkinson's Disease: Diagnostic Links. <i>Movement Disorders</i> , 2016, 31, 791-801.	2.2	125

#	ARTICLE	IF	CITATIONS
181	A53T in a parkinsonian family: a clinical update of the SNCA phenotypes. <i>Journal of Neural Transmission</i> , 2016, 123, 1301-1307.	1.4	29
182	Hyperkinetic disorders and loss of synaptic downscaling. <i>Nature Neuroscience</i> , 2016, 19, 868-875.	7.1	98
183	Prognostic factors in children with PRES and hematologic diseases. <i>Acta Neurologica Scandinavica</i> , 2016, 134, 474-483.	1.0	27
184	Memantine alters striatal plasticity inducing a shift of synaptic responses toward long-term depression. <i>Neuropharmacology</i> , 2016, 101, 341-350.	2.0	16
185	Alpha-Synuclein Produces Early Behavioral Alterations via Striatal Cholinergic Synaptic Dysfunction by Interacting With GluN2D N-Methyl-D-Aspartate Receptor Subunit. <i>Biological Psychiatry</i> , 2016, 79, 402-414.	0.7	77
186	Neuroprotection as a Potential Therapeutic Perspective in Neurodegenerative Diseases: Focus on Antiepileptic Drugs. <i>Neurochemical Research</i> , 2016, 41, 340-352.	1.6	14
187	Modulation of serotonergic transmission by eltoprazine in L-DOPA-induced dyskinesia: Behavioral, molecular, and synaptic mechanisms. <i>Neurobiology of Disease</i> , 2016, 86, 140-153.	2.1	53
188	Interferon- β 1a modulates glutamate neurotransmission in the CNS through CaMKII and GluN2A-containing NMDA receptors. <i>Neuropharmacology</i> , 2016, 100, 98-105.	2.0	17
189	Interaction between basal ganglia and limbic circuits in learning and memory processes. <i>Parkinsonism and Related Disorders</i> , 2016, 22, S65-S68.	1.1	18
190	Retinopathy during interferon- β 2 treatment for multiple sclerosis: case report and review of the literature. <i>Journal of Neurology</i> , 2016, 263, 422-427.	1.8	12
191	P066. Migraine with aura in the locker room: 4 case reports. <i>Journal of Headache and Pain</i> , 2015, 16, A169.	2.5	0
192	Biological substrates of migraine. <i>Journal of Headache and Pain</i> , 2015, 16, A19.	2.5	1
193	Migraine and epilepsy: what value today?. <i>Journal of Headache and Pain</i> , 2015, 16, A44.	2.5	2
194	O064. Antiepileptic drugs in migraine and epilepsy disorders: who is at increased risk of adverse events?. <i>Journal of Headache and Pain</i> , 2015, 16, A69.	2.5	0
195	HDAC3 role in medication consumption in medication overuse headache patients: a pilot study. <i>Human Genomics</i> , 2015, 9, 30.	1.4	7
196	Endogenous 17 β -estradiol is required for activity-dependent long-term potentiation in the striatum: interaction with the dopaminergic system. <i>Frontiers in Cellular Neuroscience</i> , 2015, 9, 192.	1.8	43
197	NMDA receptor GluN2A/GluN2B subunit ratio as synaptic trait of levodopa-induced dyskinesias: from experimental models to patients. <i>Frontiers in Cellular Neuroscience</i> , 2015, 9, 245.	1.8	68
198	Neo-synthesis of estrogenic or androgenic neurosteroids determine whether long-term potentiation or depression is induced in hippocampus of male rat. <i>Frontiers in Cellular Neuroscience</i> , 2015, 9, 376.	1.8	25

#	ARTICLE	IF	CITATIONS
199	Levodopa-induced plasticity: a double-edged sword in Parkinson's disease?. <i>Philosophical Transactions of the Royal Society B: Biological Sciences</i> , 2015, 370, 20140184.	1.8	71
200	Evidence of hydrogen sulfide involvement in amyotrophic lateral sclerosis. <i>Annals of Neurology</i> , 2015, 77, 697-709.	2.8	45
201	Synaptic plasticity and experimental autoimmune encephalomyelitis: implications for multiple sclerosis. <i>Brain Research</i> , 2015, 1621, 205-213.	1.1	30
202	The validation of an Italian version of the Freezing of Gait Questionnaire. <i>Neurological Sciences</i> , 2015, 36, 759-764.	0.9	19
203	Magnetization transfer MRI in dementia disorders, Huntington's disease and parkinsonism. <i>Journal of the Neurological Sciences</i> , 2015, 353, 1-8.	0.3	21
204	Selective loss of glucocerebrosidase activity in sporadic Parkinson's disease and dementia with Lewy bodies. <i>Molecular Neurodegeneration</i> , 2015, 10, 15.	4.4	120
205	Migraine-specific quality of life questionnaire and relapse of medication overuse headache. <i>BMC Neurology</i> , 2015, 15, 85.	0.8	10
206	The changing tree in Parkinson's disease. <i>Nature Neuroscience</i> , 2015, 18, 1196-1198.	7.1	7
207	Multitarget disease-modifying therapy in Parkinson's disease?. <i>Lancet Neurology</i> , The, 2015, 14, 975-976.	4.9	16
208	Region- and age-dependent reductions of hippocampal long-term potentiation and NMDA to AMPA ratio in a genetic model of Alzheimer's disease. <i>Neurobiology of Aging</i> , 2015, 36, 123-133.	1.5	30
209	Abnormal cortical lysosomal β -hexosaminidase and β -galactosidase activity at post-synaptic sites during Alzheimer's disease progression. <i>International Journal of Biochemistry and Cell Biology</i> , 2015, 58, 62-70.	1.2	23
210	Derangement of Ras-Guanine Nucleotide-Releasing Factor 1 (Ras-GRF1) and Extracellular Signal-Regulated Kinase (ERK) Dependent Striatal Plasticity in L-DOPA-Induced Dyskinesia. <i>Biological Psychiatry</i> , 2015, 77, 106-115.	0.7	67
211	Factors Influencing the Measurement of Lysosomal Enzymes Activity in Human Cerebrospinal Fluid. <i>PLoS ONE</i> , 2014, 9, e101453.	1.1	23
212	Differential role of CSF alpha-synuclein species, tau, and A β 42 in Parkinson's Disease. <i>Frontiers in Aging Neuroscience</i> , 2014, 6, 53.	1.7	139
213	Ischemic Stroke Injury Is Mediated by Aberrant Cdk5. <i>Journal of Neuroscience</i> , 2014, 34, 8259-8267.	1.7	73
214	Infliximab monotherapy for neuro-Behçet's disease: A case report. <i>Journal of the Neurological Sciences</i> , 2014, 347, 389-390.	0.3	8
215	Subclinical Visuospatial Impairment in Parkinson's Disease: The Role of Basal Ganglia and Limbic System. <i>Frontiers in Neurology</i> , 2014, 5, 152.	1.1	13
216	Long term headache duration is a factor predicting nonresponse to detoxification and advice in medication overuse headache. <i>Journal of Headache and Pain</i> , 2014, 15, 88.	2.5	5

#	ARTICLE	IF	CITATIONS
217	Sodium valproate in migraine without aura and medication overuse headache: A randomized controlled trial. <i>European Neuropsychopharmacology</i> , 2014, 24, 1289-1297.	0.3	55
218	Interferon- γ 1a protects neurons against mitochondrial toxicity via modulation of STAT1 signaling: Electrophysiological evidence. <i>Neurobiology of Disease</i> , 2014, 62, 387-393.	2.1	17
219	Scientific research of Italian neurologists from 2008 to 2011. <i>Neurological Sciences</i> , 2014, 35, 437-442.	0.9	3
220	Lower urinary tract symptoms and urodynamic dysfunction in clinically isolated syndromes suggestive of multiple sclerosis. <i>European Journal of Neurology</i> , 2014, 21, 648-653.	1.7	17
221	A novel ATP1A2 gene mutation in familial hemiplegic migraine and epilepsy. <i>Cephalalgia</i> , 2014, 34, 68-72.	1.8	28
222	Biomarker time out. <i>Multiple Sclerosis Journal</i> , 2014, 20, 1560-1563.	1.4	4
223	Lysosomal enzyme activities in human brain. <i>Journal of Biotechnology</i> , 2014, 185, S7.	1.9	0
224	L-DOPA reverses the impairment of Dentate Gyrus LTD in experimental parkinsonism via β -adrenergic receptors. <i>Experimental Neurology</i> , 2014, 261, 377-385.	2.0	9
225	c-Jun N-terminal kinase has a key role in Alzheimer disease synaptic dysfunction in vivo. <i>Cell Death and Disease</i> , 2014, 5, e1019-e1019.	2.7	88
226	Targeting metabotropic glutamate receptors as a new strategy against levodopa-induced dyskinesia in Parkinson's disease?. <i>Movement Disorders</i> , 2014, 29, 715-719.	2.2	14
227	Cerebrospinal fluid lysosomal enzymes and alpha-synuclein in Parkinson's disease. <i>Movement Disorders</i> , 2014, 29, 1019-1027.	2.2	223
228	Direct and indirect pathways of basal ganglia: a critical reappraisal. <i>Nature Neuroscience</i> , 2014, 17, 1022-1030.	7.1	598
229	Brain arteriovenous malformations and seizures: an Italian study. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2014, 85, 284-288.	0.9	44
230	Shapiro's syndrome: Defining the clinical spectrum of the spontaneous paroxysmal hypothermia syndrome. <i>European Journal of Paediatric Neurology</i> , 2014, 18, 453-457.	0.7	28
231	Environmental enrichment restores CA1 hippocampal LTP and reduces severity of seizures in epileptic mice. <i>Experimental Neurology</i> , 2014, 261, 320-327.	2.0	25
232	Diagnostic Accuracy of Parkinson Disease by Support Vector Machine (SVM) Analysis of 123I-FP-CIT Brain SPECT Data. <i>Medicine (United States)</i> , 2014, 93, e228.	0.4	28
233	Low dopamine nigrostriatal synapses in the heterozygous PINK1 mouse model of familial Parkinson's disease. <i>Movement Disorders</i> , 2014, 29, 11-14.	2.2	2
234	Entacapone Reduces Cortical Activation in Parkinson's Disease with Wearing-Off: A f-MRI Study. <i>PLoS ONE</i> , 2014, 9, e96806.	1.1	13

#	ARTICLE	IF	CITATIONS
235	Glutamate Receptors and Levodopa-Induced Dyskinesia. , 2014, , 229-243.		2
236	Changes in endolysosomal enzyme activities in cerebrospinal fluid of patients with Parkinson's disease. <i>Movement Disorders</i> , 2013, 28, 747-754.	2.2	88
237	New experimental and clinical links between the hippocampus and the dopaminergic system in Parkinson's disease. <i>Lancet Neurology</i> , The, 2013, 12, 811-821.	4.9	165
238	Rhes, a key element of selective neuronal vulnerability in Huntington's disease: A striatal-specific license to kill during energy metabolism failure. <i>Movement Disorders</i> , 2013, 28, 735-735.	2.2	2
239	Region-specific restoration of striatal synaptic plasticity by dopamine grafts in experimental parkinsonism. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2013, 110, E4375-84.	3.3	26
240	Cortical spreading depression as a target for anti-migraine agents. <i>Journal of Headache and Pain</i> , 2013, 14, 62.	2.5	110
241	Effects of central and peripheral inflammation on hippocampal synaptic plasticity. <i>Neurobiology of Disease</i> , 2013, 52, 229-236.	2.1	155
242	Cerebrospinal fluid biomarkers in Parkinson disease. <i>Nature Reviews Neurology</i> , 2013, 9, 131-140.	4.9	177
243	Ischemic-LTP in Striatal Spiny Neurons of both Direct and Indirect Pathway Requires the Activation of D1-Like Receptors and NO/Soluble Guanylate Cyclase/cGMP Transmission. <i>Journal of Cerebral Blood Flow and Metabolism</i> , 2013, 33, 278-286.	2.4	13
244	BDNF- α -TrkB signaling in striatopallidal neurons controls inhibition of locomotor behavior. <i>Nature Communications</i> , 2013, 4, 2031.	5.8	40
245	Protective Effects of Zonisamide Against Rotenone-Induced Neurotoxicity. <i>Neurochemical Research</i> , 2013, 38, 2631-2639.	1.6	17
246	New synaptic and molecular targets for neuroprotection in Parkinson's disease. <i>Movement Disorders</i> , 2013, 28, 51-60.	2.2	34
247	A pathophysiological link between dystonia, striatal interneurons and neuropeptide Y. <i>Brain</i> , 2013, 136, 1341-1344.	3.7	3
248	Expression of cathepsins S and D signals a distinctive biochemical trait in CD34 ⁺ hematopoietic stem cells of relapsing-remitting multiple sclerosis patients. <i>Multiple Sclerosis Journal</i> , 2013, 19, 1443-1453.	1.4	12
249	Modulatory role of androgenic and estrogenic neurosteroids in determining the direction of synaptic plasticity in the CA1 hippocampal region of male rats. <i>Physiological Reports</i> , 2013, 1, e00185.	0.7	29
250	Complexity of Motor Sequences and Cortical Reorganization in Parkinson's Disease: A Functional MRI Study. <i>PLoS ONE</i> , 2013, 8, e66834.	1.1	27
251	Immunological Profile of Silent Brain Infarction and Lacunar Stroke. <i>PLoS ONE</i> , 2013, 8, e68428.	1.1	20
252	Recurrent hyperCKemia with normal muscle biopsy in a pediatric patient with neuromyelitis optica. <i>Neurology</i> , 2012, 79, 1182-1184.	1.5	27

#	ARTICLE	IF	CITATIONS
253	Rebalance of Striatal NMDA/AMPA Receptor Ratio Underlies the Reduced Emergence of Dyskinesia During D2-Like Dopamine Agonist Treatment in Experimental Parkinson's Disease. <i>Journal of Neuroscience</i> , 2012, 32, 17921-17931.	1.7	67
254	Nociceptin/Orphanin FQ Receptor Agonists Attenuate L-DOPA-Induced Dyskinesias. <i>Journal of Neuroscience</i> , 2012, 32, 16106-16119.	1.7	39
255	Critical role of calcitonin gene-related peptide receptors in cortical spreading depression. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2012, 109, 18985-18990.	3.3	113
256	N-Methyl-d-aspartate (NMDA) Receptor Composition Modulates Dendritic Spine Morphology in Striatal Medium Spiny Neurons. <i>Journal of Biological Chemistry</i> , 2012, 287, 18103-18114.	1.6	38
257	Performance of A β ¹⁻⁴⁰ , A β ¹⁻⁴² , Total Tau, and Phosphorylated Tau as Predictors of Dementia in a Cohort of Patients with Mild Cognitive Impairment. <i>Journal of Alzheimer's Disease</i> , 2012, 29, 229-238.	1.2	93
258	Mechanisms underlying altered striatal synaptic plasticity in old A53T- α synuclein overexpressing mice. <i>Neurobiology of Aging</i> , 2012, 33, 1792-1799.	1.5	37
259	Targeting NR2A-containing NMDA receptors reduces L-DOPA-induced dyskinesias. <i>Neurobiology of Aging</i> , 2012, 33, 2138-2144.	1.5	60
260	Functional interactions within striatal microcircuit in animal models of Huntington's disease. <i>Neuroscience</i> , 2012, 211, 165-184.	1.1	17
261	The validity and reliability of the Italian Olfactory Identification Test (IOIT) in healthy subjects and in Parkinson's disease patients. <i>Parkinsonism and Related Disorders</i> , 2012, 18, 788-793.	1.1	31
262	A2A Adenosine Receptor Antagonism Enhances Synaptic and Motor Effects of Cocaine via CB1 Cannabinoid Receptor Activation. <i>PLoS ONE</i> , 2012, 7, e38312.	1.1	18
263	Clinical Aspects and Management of Levodopa-Induced Dyskinesia. <i>Parkinson's Disease</i> , 2012, 2012, 1-12.	0.6	21
264	Corticostriatal Plastic Changes in Experimental L-DOPA-Induced Dyskinesia. <i>Parkinson's Disease</i> , 2012, 2012, 1-10.	0.6	15
265	Role of the dorsal hippocampus in object memory load. <i>Learning and Memory</i> , 2012, 19, 211-218.	0.5	45
266	Rhes-mTORC1 interaction: A new possible therapeutic target in Parkinson's disease and L-dopa-induced dyskinesia?. <i>Movement Disorders</i> , 2012, 27, 815-815.	2.2	3
267	Synaptic Dysfunction in Parkinson's Disease. <i>Advances in Experimental Medicine and Biology</i> , 2012, 970, 553-572.	0.8	209
268	Mechanisms underlying the impairment of hippocampal long-term potentiation and memory in experimental Parkinson's disease. <i>Brain</i> , 2012, 135, 1884-1899.	3.7	124
269	Prenatal stress and hippocampal BDNF expression: a fading imperative. <i>Journal of Physiology</i> , 2012, 590, 1309-1310.	1.3	4
270	Coenzyme Q10, Hyperhomocysteinemia and MTHFR C677T Polymorphism in Levodopa-treated Parkinson's Disease Patients. <i>NeuroMolecular Medicine</i> , 2012, 14, 84-90.	1.8	45

#	ARTICLE	IF	CITATIONS
271	Theta-burst stimulation and striatal plasticity in experimental parkinsonism. <i>Experimental Neurology</i> , 2012, 236, 395-398.	2.0	23
272	Migraine with aura in the locker room: three case reports. <i>Journal of Headache and Pain</i> , 2012, 13, 91-93.	2.5	7
273	Medication Overuse Headache: Causes, Consequences, and Treatment. , 2012, , 351-362.		0
274	Striatum-hippocampus balance: From physiological behavior to interneuronal pathology. <i>Progress in Neurobiology</i> , 2011, 94, 102-114.	2.8	43
275	Neural 17 β -estradiol facilitates long-term potentiation in the hippocampal CA1 region. <i>Neuroscience</i> , 2011, 192, 67-73.	1.1	50
276	CSF Levels of Heart Fatty Acid Binding Protein are Altered During Early Phases of Alzheimer's Disease. <i>Journal of Alzheimer's Disease</i> , 2011, 22, 1281-1288.	1.2	49
277	A magnetization transfer study of mild and advanced Parkinson's disease. <i>European Journal of Neurology</i> , 2011, 18, 471-477.	1.7	33
278	A novel spinocerebellar ataxia type 15 family with involuntary movements and cognitive decline. <i>European Journal of Neurology</i> , 2011, 18, 1263-1265.	1.7	24
279	Ictal Epileptic Headache Mimicking Status Migrainosus: EEG and DWI-MRI Findings. <i>Headache</i> , 2011, 51, 160-162.	1.8	37
280	A critical role of NO/cGMP/PKG dependent pathway in hippocampal post-ischemic LTP: Modulation by zonisamide. <i>Neurobiology of Disease</i> , 2011, 44, 185-191.	2.1	23
281	Higher free d-aspartate and N-methyl-d-aspartate levels prevent striatal depotentiation and anticipate l-DOPA-induced dyskinesia. <i>Experimental Neurology</i> , 2011, 232, 240-250.	2.0	39
282	Hippocampal enlargement in Bassoon-mutant mice is associated with enhanced neurogenesis, reduced apoptosis, and abnormal BDNF levels. <i>Cell and Tissue Research</i> , 2011, 346, 11-26.	1.5	23
283	Heterozygous X-linked adrenoleukodystrophy-associated myelopathy mimicking primary progressive multiple sclerosis. <i>Journal of Neurology</i> , 2011, 258, 323-324.	1.8	12
284	Levodopa-induced breathing, cognitive and behavioral changes in Parkinson's disease. <i>Journal of Neurology</i> , 2011, 258, 2296-2299.	1.8	10
285	Migraine and psychiatric comorbidity: a review of clinical findings. <i>Journal of Headache and Pain</i> , 2011, 12, 115-125.	2.5	301
286	Mortalin inhibition in experimental Parkinson's disease. <i>Movement Disorders</i> , 2011, 26, 1639-1647.	2.2	21
287	Cerebrospinal fluid Tau/synuclein ratio in Parkinson's disease and degenerative dementias. <i>Movement Disorders</i> , 2011, 26, 1428-1435.	2.2	161
288	c-Jun N-terminal Kinase Regulates Soluble A β Oligomers and Cognitive Impairment in AD Mouse Model. <i>Journal of Biological Chemistry</i> , 2011, 286, 43871-43880.	1.6	74

#	ARTICLE	IF	CITATIONS
289	Dopamine-Dependent Long-Term Depression Is Expressed in Striatal Spiny Neurons of Both Direct and Indirect Pathways: Implications for Parkinson's Disease. <i>Journal of Neuroscience</i> , 2011, 31, 12513-12522.	1.7	94
290	Palinopsia in patients with migraine: A case-control study. <i>Cephalalgia</i> , 2011, 31, 999-1004.	1.8	33
291	Migraine preventive drug-induced weight gain may be mediated by effects on hypothalamic peptides: The results of a pilot study. <i>Cephalalgia</i> , 2011, 31, 543-549.	1.8	16
292	Occipital arteriovenous malformations and migraine. <i>Cephalalgia</i> , 2011, 31, 1320-1324.	1.8	25
293	Inhibition of phosphodiesterases rescues striatal long-term depression and reduces levodopa-induced dyskinesia. <i>Brain</i> , 2011, 134, 375-387.	3.7	125
294	The Distinct Role of Medium Spiny Neurons and Cholinergic Interneurons in the D ₂ /A _{2A} Receptor Interaction in the Striatum: Implications for Parkinson's Disease. <i>Journal of Neuroscience</i> , 2011, 31, 1850-1862.	1.7	140
295	Mitochondria and the Link Between Neuroinflammation and Neurodegeneration. <i>Journal of Alzheimer's Disease</i> , 2010, 20, S369-S379.	1.2	118
296	A young patient with type C multiple system atrophy and hereditary hemochromatosis. <i>Journal of Neurology</i> , 2010, 257, 294-295.	1.8	3
297	Levodopa-induced dyskinesias in patients with Parkinson's disease: filling the bench-to bedside gap. <i>Lancet Neurology</i> , The, 2010, 9, 1106-1117.	4.9	329
298	Medication overuse headache: Neurobiological, behavioural and therapeutic aspects. <i>Pain</i> , 2010, 150, 222-224.	2.0	30
299	Myostatin depletion: A therapy for Ehlers-Danlos syndrome?. <i>Annals of Neurology</i> , 2010, 67, 147-148.	2.8	4
300	L-DOPA-induced sprouting of serotonin axon terminals: A useful biomarker for dyskinesias?. <i>Annals of Neurology</i> , 2010, 68, 578-580.	2.8	10
301	Direct and indirect pathways in levodopa-induced dyskinesia: A more complex matter than a network imbalance. <i>Movement Disorders</i> , 2010, 25, 1527-1529.	2.2	5
302	Hyperhomocysteinemia recurrence in levodopa-treated Parkinson's disease patients. <i>European Journal of Neurology</i> , 2010, 17, 661-665.	1.7	15
303	Hyperhomocysteinemia in epileptic patients on new antiepileptic drugs. <i>Epilepsia</i> , 2010, 51, 274-279.	2.6	84
304	Brain's traffic lights. <i>Nature</i> , 2010, 466, 449-449.	18.7	10
305	A53T-Alpha-Synuclein Overexpression Impairs Dopamine Signaling and Striatal Synaptic Plasticity in Old Mice. <i>PLoS ONE</i> , 2010, 5, e11464.	1.1	119
306	Synaptic dysfunction in Parkinson's disease. <i>Biochemical Society Transactions</i> , 2010, 38, 493-497.	1.6	96

#	ARTICLE	IF	CITATIONS
307	A Combination of CSF Tau Ratio and Midsagittal Midbrain atrophy for the Early Diagnosis of Progressive Supranuclear Palsy. <i>Journal of Alzheimer's Disease</i> , 2010, 22, 195-203.	1.2	18
308	Distinct Levels of Dopamine Denervation Differentially Alter Striatal Synaptic Plasticity and NMDA Receptor Subunit Composition. <i>Journal of Neuroscience</i> , 2010, 30, 14182-14193.	1.7	155
309	Assemblies of glutamate receptor subunits with post-synaptic density proteins and their alterations in Parkinson's disease. <i>Progress in Brain Research</i> , 2010, 183, 169-182.	0.9	41
310	TrkB/BDNF-Dependent Striatal Plasticity and Behavior in a Genetic Model of Epilepsy: Modulation by Valproic Acid. <i>Neuropsychopharmacology</i> , 2010, 35, 1531-1540.	2.8	32
311	Impaired Plasticity at Specific Subset of Striatal Synapses in the Ts65Dn Mouse Model of Down Syndrome. <i>Biological Psychiatry</i> , 2010, 67, 666-671.	0.7	28
312	Hippocampal Synaptic Plasticity, Memory, and Epilepsy: Effects of Long-Term Valproic Acid Treatment. <i>Biological Psychiatry</i> , 2010, 67, 567-574.	0.7	68
313	Downstream mechanisms triggered by mitochondrial dysfunction in the basal ganglia: From experimental models to neurodegenerative diseases. <i>Biochimica Et Biophysica Acta - Molecular Basis of Disease</i> , 2010, 1802, 151-161.	1.8	31
314	Vomiting due to intravenous levetiracetam in a case of Creutzfeldt-Jakob disease. <i>Epilepsy and Behavior</i> , 2010, 17, 133.	0.9	4
315	Seizure aggravation caused by antiepileptic drugs in a patient with muscle-eye-brain disease. <i>Epilepsy and Behavior</i> , 2010, 19, 666-668.	0.9	3
316	Electrophysiological actions of zonisamide on striatal neurons: Selective neuroprotection against complex I mitochondrial dysfunction. <i>Experimental Neurology</i> , 2010, 221, 217-224.	2.0	28
317	mTOR inhibitor rapamycin suppresses striatal post-ischemic LTP. <i>Experimental Neurology</i> , 2010, 226, 328-331.	2.0	23
318	Aortic stiffness and pulse wave reflection in young subjects with migraine. <i>Neurology</i> , 2010, 75, 960-966.	1.5	53
319	Regulation of Corticostriatal Synaptic Plasticity in Physiological and Pathological Conditions. <i>Handbook of Behavioral Neuroscience</i> , 2010, , 219-229.	0.7	0
320	Decreased NR2B Subunit Synaptic Levels Cause Impaired Long-Term Potentiation But Not Long-Term Depression. <i>Journal of Neuroscience</i> , 2009, 29, 669-677.	1.7	126
321	Teaching Neuro Images: Acute tetraparesis. <i>Neurology</i> , 2009, 73, e58.	1.5	3
322	Cerebrospinal fluid β -glucocerebrosidase activity is reduced in Dementia with Lewy Bodies. <i>Neurobiology of Disease</i> , 2009, 34, 484-486.	2.1	61
323	Epilepsy-induced abnormal striatal plasticity in Bassoon mutant mice. <i>European Journal of Neuroscience</i> , 2009, 29, 1979-1993.	1.2	26
324	Obsessive-Compulsive Disorder and Migraine With Medication-Overuse Headache. <i>Headache</i> , 2009, 49, 1005-1013.	1.8	56

#	ARTICLE	IF	CITATIONS
325	A2A adenosine receptor antagonists protect the striatum against rotenone-induced neurotoxicity. <i>Experimental Neurology</i> , 2009, 217, 231-234.	2.0	19
326	Short-term and long-term plasticity at corticostriatal synapses: Implications for learning and memory. <i>Behavioural Brain Research</i> , 2009, 199, 108-118.	1.2	115
327	Pattern of Tau forms in CSF is altered in progressive supranuclear palsy. <i>Neurobiology of Aging</i> , 2009, 30, 34-40.	1.5	85
328	Induction of heat shock protein 70 reduces the alteration of striatal electrical activity caused by mitochondrial impairment. <i>Neuroscience</i> , 2009, 163, 735-740.	1.1	26
329	Pathophysiological basis of migraine prophylaxis. <i>Progress in Neurobiology</i> , 2009, 89, 176-192.	2.8	100
330	1.4 INCREASED AORTIC STIFFNESS IN YOUNG SUBJECTS WITH MIGRAINE. <i>Artery Research</i> , 2009, 3, 151.	0.3	0
331	Basi neurobiologiche dei deficit cognitivi nella malattia di Parkinson. , 2009, , 99-113.		0
332	Endocannabinoids in platelets of chronic migraine patients and medication-overuse headache patients: relation with serotonin levels. <i>European Journal of Clinical Pharmacology</i> , 2008, 64, 1-8.	0.8	77
333	Acute dystonia induced by the combination of midodrine and perphenazine. <i>Journal of Neurology</i> , 2008, 255, 767-768.	1.8	8
334	Parkinsonism and cognitive impairment following chronic exposure to potassium cyanide. <i>Movement Disorders</i> , 2008, 23, 468-470.	2.2	29
335	Molecular mechanisms underlying levodopa-induced dyskinesia. <i>Movement Disorders</i> , 2008, 23, S570-S579.	2.2	99
336	Hyperhomocysteinemia and retinal vascular changes in patients with epilepsy. <i>Epilepsy Research</i> , 2008, 81, 86-89.	0.8	5
337	Levetiracetam in newly diagnosed late-onset post-stroke seizures: A prospective observational study. <i>Epilepsy Research</i> , 2008, 82, 223-226.	0.8	62
338	Association Between Migraine and Headache Attributed to Stroke: A Caseâ€“Control Study. <i>Headache</i> , 2008, 48, 1468-1475.	1.8	7
339	CSF proteome analysis in multiple sclerosis patients by twoâ€“dimensional electrophoresis. <i>European Journal of Neurology</i> , 2008, 15, 998-1001.	1.7	34
340	A ¹ H magnetic resonance spectroscopy study in patients with obstructive sleep apnea. <i>European Journal of Neurology</i> , 2008, 15, 1058-1064.	1.7	34
341	Involvement of Corticotrophin-Releasing Factor and Orexin-A in Chronic Migraine and Medication-Overuse Headache: Findings From Cerebrospinal Fluid. <i>Cephalalgia</i> , 2008, 28, 714-722.	1.8	94
342	Antiepileptic Drugs on Calcium Currents Recorded from Cortical and PAG Neurons: Therapeutic Implications for Migraine. <i>Cephalalgia</i> , 2008, 28, 1315-1326.	1.8	37

#	ARTICLE	IF	CITATIONS
343	l-DOPA dosage is critically involved in dyskinesia via loss of synaptic depotentiation. <i>Neurobiology of Disease</i> , 2008, 29, 327-335.	2.1	105
344	Degradation of endocannabinoids in chronic migraine and medication overuse headache. <i>Neurobiology of Disease</i> , 2008, 30, 186-189.	2.1	71
345	Abnormal Striatal GABA Transmission in the Mouse Model for the Fragile X Syndrome. <i>Biological Psychiatry</i> , 2008, 63, 963-973.	0.7	157
346	Cerebrospinal Fluid Biomarkers in Parkinson's Disease with Dementia and Dementia with Lewy Bodies. <i>Biological Psychiatry</i> , 2008, 64, 850-855.	0.7	164
347	NF- κ B/NOS cross-talk induced by mitochondrial complex II inhibition: Implications for Huntington's disease. <i>Neuroscience Letters</i> , 2008, 434, 241-246.	1.0	40
348	Fibroblast growth factor-2 levels are elevated in the cerebrospinal fluid of multiple sclerosis patients. <i>Neuroscience Letters</i> , 2008, 435, 223-228.	1.0	52
349	ACh/Dopamine Crosstalk in Motor Control and Reward: A Crucial Role for α 6-Containing Nicotinic Receptors?. <i>Neuron</i> , 2008, 60, 4-7.	3.8	22
350	Plasticity and repair in the post-ischemic brain. <i>Neuropharmacology</i> , 2008, 55, 353-362.	2.0	132
351	Acetyl-L-Carnitine selectively prevents post-ischemic LTP via a possible action on mitochondrial energy metabolism. <i>Neuropharmacology</i> , 2008, 55, 223-229.	2.0	25
352	Striatal synaptic changes in experimental parkinsonism: Role of NMDA receptor trafficking in PSD. <i>Parkinsonism and Related Disorders</i> , 2008, 14, S145-S149.	1.1	14
353	Neuroinflammation and synaptic plasticity: theoretical basis for a novel, immune-centred, therapeutic approach to neurological disorders. <i>Trends in Pharmacological Sciences</i> , 2008, 29, 402-412.	4.0	172
354	Nerve growth factor and brain-derived neurotrophic factor: potential targets for migraine treatment?. <i>Expert Opinion on Therapeutic Patents</i> , 2008, 18, 705-721.	2.4	1
355	Synaptic plasticity, dopamine and Parkinson's disease: one step ahead. <i>Brain</i> , 2008, 132, 285-287.	3.7	50
356	Abnormalities in the cerebrospinal fluid levels of endocannabinoids in multiple sclerosis. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2008, 79, 1224-1229.	0.9	70
357	The Endocannabinoid System in Parkinson's Disease. <i>Current Pharmaceutical Design</i> , 2008, 14, 2337-2346.	0.9	52
358	Tau forms in CSF as a reliable biomarker for progressive supranuclear palsy. <i>Neurology</i> , 2008, 71, 1796-1803.	1.5	101
359	Electrophysiology and Pharmacology of Striatal Neuronal Dysfunction Induced by Mitochondrial Complex I Inhibition. <i>Journal of Neuroscience</i> , 2008, 28, 8040-8052.	1.7	54
360	The Brain Cytoplasmic RNA BC1 Regulates Dopamine D2 Receptor-Mediated Transmission in the Striatum. <i>Journal of Neuroscience</i> , 2007, 27, 8885-8892.	1.7	46

#	ARTICLE	IF	CITATIONS
361	Na ⁺ /Ca ²⁺ Exchanger Maintains Ionic Homeostasis in the Peri-Infarct Area. <i>Stroke</i> , 2007, 38, 1614-1620.	1.0	11
362	Ischemic bilateral hippocampal dysfunction during transient global amnesia. <i>Neurology</i> , 2007, 69, 493-493.	1.5	22
363	Production of brain-derived neurotrophic factor by mononuclear cells of patients with multiple sclerosis treated with glatiramer acetate, interferon- β 1a, and high doses of immunoglobulins. <i>Multiple Sclerosis Journal</i> , 2007, 13, 313-331.	1.4	58
364	Multiple Cranial Nerve Palsies in a Patient with Internal Carotid Artery Dissection. <i>European Neurology</i> , 2007, 58, 125-127.	0.6	8
365	Dopamine-mediated regulation of corticostriatal synaptic plasticity. <i>Trends in Neurosciences</i> , 2007, 30, 211-219.	4.2	707
366	Antiepileptic drugs in migraine: from clinical aspects to cellular mechanisms. <i>Trends in Pharmacological Sciences</i> , 2007, 28, 188-195.	4.0	96
367	Interaction of A2A adenosine and D2 dopamine receptors modulates corticostriatal glutamatergic transmission. <i>Neuropharmacology</i> , 2007, 53, 783-789.	2.0	53
368	Memantine reduces neuronal dysfunctions triggered by in vitro ischemia and 3-nitropropionic acid. <i>Experimental Neurology</i> , 2007, 207, 218-226.	2.0	32
369	Plastic abnormalities in experimental Huntington's disease. <i>Current Opinion in Pharmacology</i> , 2007, 7, 106-111.	1.7	30
370	Neuronal networks and synaptic plasticity in Parkinson's disease: beyond motor deficits. <i>Parkinsonism and Related Disorders</i> , 2007, 13, S259-S262.	1.1	55
371	Increased Levels of Neurotrophins Are Not Specific for Chronic Migraine: Evidence From Primary Fibromyalgia Syndrome. <i>Journal of Pain</i> , 2007, 8, 737-745.	0.7	132
372	Differences in Extracellular Matrix Production and Basic Fibroblast Growth Factor Response in Skin Fibroblasts from Sporadic and Familial Alzheimer's Disease. <i>Molecular Medicine</i> , 2007, 13, 542-550.	1.9	31
373	Prevalence of essential tremor in the territory of Lake Trasimeno, Italy: Results of a population-based study. <i>Movement Disorders</i> , 2007, 22, 540-545.	2.2	26
374	Lysosomal hydrolases in cerebrospinal fluid from subjects with Parkinson's disease. <i>Movement Disorders</i> , 2007, 22, 1481-1484.	2.2	103
375	Occipital pseudoaneurysm as a complication of extension channel placement for DBS in Parkinson's disease. <i>Movement Disorders</i> , 2007, 22, 1834-1836.	2.2	11
376	Application of the ICHD-II Criteria to the Diagnosis of Primary Chronic Headaches Via a Computerized Structured Record. <i>Headache</i> , 2007, 47, 38-44.	1.8	7
377	Language Disturbances as a Side Effect of Prophylactic Treatment of Migraine. <i>Headache</i> , 2007, 48, 070623002213001-???	1.8	13
378	Levetiracetam monotherapy in Alzheimer patients with late-onset seizures: a prospective observational study. <i>European Journal of Neurology</i> , 2007, 14, 1176-1178.	1.7	81

#	ARTICLE	IF	CITATIONS
379	Neuroacanthocytosis associated with a defect of the 4.1R membrane protein. <i>BMC Neurology</i> , 2007, 7, 4.	0.8	6
380	Synaptic plasticity during recovery from permanent occlusion of the middle cerebral artery. <i>Neurobiology of Disease</i> , 2007, 27, 44-53.	2.1	63
381	Expression of ionotropic glutamate receptor GLUR3 and effects of glutamate on MBP- and MOG-specific lymphocyte activation and chemotactic migration in multiple sclerosis patients. <i>Journal of Neuroimmunology</i> , 2007, 188, 146-158.	1.1	41
382	Skin biopsy: a new diagnostic tool for autonomic dysfunctions in Parkinson's disease?. <i>Lancet Neurology</i> , The, 2007, 6, 848-849.	4.9	12
383	Endocannabinoids in Chronic Migraine: CSF Findings Suggest a System Failure. <i>Neuropsychopharmacology</i> , 2007, 32, 1384-1390.	2.8	115
384	Mapping P2X and P2Y receptor proteins in striatum and substantia nigra: An immunohistological study. <i>Purinergic Signalling</i> , 2007, 3, 389-398.	1.1	69
385	Striatal metabotropic glutamate receptors as a target for pharmacotherapy in Parkinson's disease. <i>Amino Acids</i> , 2007, 32, 189-195.	1.2	39
386	Sensitization, glutamate, and the link between migraine and fibromyalgia. <i>Current Pain and Headache Reports</i> , 2007, 11, 343-351.	1.3	95
387	Effect of MTHFR Polymorphisms on Hyperhomocysteinemia in Levodopa-treated Parkinsonian Patients. <i>NeuroMolecular Medicine</i> , 2007, 9, 249-254.	1.8	26
388	Practical Considerations for the Treatment of Elderly Patients with Migraine. <i>Drugs and Aging</i> , 2006, 23, 461-489.	1.3	22
389	Chronic Cocaine Prevents Depotentiation at Corticostriatal Synapses. <i>Biological Psychiatry</i> , 2006, 60, 436-443.	0.7	43
390	NR2B-containing NMDA receptors promote the neurotoxic effects of 3-nitropropionic acid but not of rotenone in the striatum. <i>Experimental Neurology</i> , 2006, 202, 470-479.	2.0	27
391	L-DOPA treatment of parkinsonian rats changes the expression of Src, Lyn and PKC kinases. <i>Neuroscience Letters</i> , 2006, 398, 211-214.	1.0	18
392	Deficits of glutamate transmission in the striatum of toxic and genetic models of Huntington's disease. <i>Neuroscience Letters</i> , 2006, 410, 6-10.	1.0	15
393	Acetyl-L-carnitine protects striatal neurons against in vitro ischemia: The role of endogenous acetylcholine. <i>Neuropharmacology</i> , 2006, 50, 917-923.	2.0	27
394	Distinct roles for spinophilin and neurabin in dopamine-mediated plasticity. <i>Neuroscience</i> , 2006, 140, 897-911.	1.1	84
395	Deficits of glutamate transmission in the striatum of experimental hemiballism. <i>Neuroscience</i> , 2006, 143, 213-221.	1.1	7
396	NR2B Subunit Exerts a Critical Role in Postischemic Synaptic Plasticity. <i>Stroke</i> , 2006, 37, 1895-1901.	1.0	63

#	ARTICLE	IF	CITATIONS
397	Clinical-Biochemical Correlates of Migraine Attacks in Rizatriptan Responders and Non-Responders. Cephalalgia, 2006, 26, 257-265.	1.8	64
398	Biochemical Changes in Endocannabinoid System are Expressed in Platelets of Female but not Male Migraineurs. Cephalalgia, 2006, 26, 277-281.	1.8	59
399	Glial Cell Line-Derived Neurotrophic Factor and Somatostatin Levels in Cerebrospinal Fluid of Patients Affected by Chronic Migraine and Fibromyalgia. Cephalalgia, 2006, 26, 409-415.	1.8	42
400	NF- κ B Activity and iNOS Expression in Monocytes from Internal Jugular Blood of Migraine Without Aura Patients During Attacks. Cephalalgia, 2006, 26, 1071-1079.	1.8	45
401	Proinflammatory Cytokines, Adhesion Molecules, and Lymphocyte Integrin Expression in the Internal Jugular Blood of Migraine Patients Without Aura Assessed Ictally. Headache, 2006, 46, 200-207.	1.8	245
402	Synaptic plasticity in the basal ganglia as a cellular model for spatial cognition and neurological disorders. Cognitive Processing, 2006, 7, 1-1.	0.7	3
403	Tiagabine and vigabatrin reduce the severity of NMDA-induced excitotoxicity in chick retina. Experimental Brain Research, 2006, 171, 511-515.	0.7	6
404	Pathways of neurodegeneration and experimental models of basal ganglia disorders: Downstream effects of mitochondrial inhibition. European Journal of Pharmacology, 2006, 545, 65-72.	1.7	22
405	A convergent model for cognitive dysfunctions in Parkinson's disease: the critical dopamine-acetylcholine synaptic balance. Lancet Neurology, The, 2006, 5, 974-983.	4.9	289
406	Plastic and behavioral abnormalities in experimental Huntington's disease: A crucial role for cholinergic interneurons. Neurobiology of Disease, 2006, 22, 143-152.	2.1	79
407	Enhanced sensitivity of DJ-1-deficient dopaminergic neurons to energy metabolism impairment: Role of Na ⁺ /K ⁺ ATPase. Neurobiology of Disease, 2006, 23, 54-60.	2.1	51
408	Multiple Mechanisms Underlying the Neuroprotective Effects of Antiepileptic Drugs Against In Vitro Ischemia. Stroke, 2006, 37, 1319-1326.	1.0	95
409	Mitochondrial Toxins in Basal Ganglia Disorders: From Animal Models to Therapeutic Strategies. Current Neuropharmacology, 2006, 4, 69-75.	1.4	23
410	A Critical Interaction between NR2B and MAGUK in L-DOPA Induced Dyskinesia. Journal of Neuroscience, 2006, 26, 2914-2922.	1.7	243
411	Giant Basilar Apex Aneurysm Presenting as Bilateral Thalamic Compression with Neuropsychological Disorders. European Neurology, 2006, 56, 57-58.	0.6	1
412	Removing Pathogenic Memories: A Neurobiology of Psychotherapy. Molecular Neurobiology, 2005, 32, 123-132.	1.9	50
413	Inhibition of Persistent Sodium Current Fraction and Voltage-gated L-type Calcium Current by Propofol in Cortical Neurons: Implications for Its Antiepileptic Activity. Epilepsia, 2005, 46, 624-635.	2.6	46
414	Striatal synaptic plasticity: Implications for motor learning and Parkinson's disease. Movement Disorders, 2005, 20, 395-402.	2.2	141

#	ARTICLE	IF	CITATIONS
415	Medicationâ€™overuse headache: pathophysiological insights. Journal of Headache and Pain, 2005, 6, 199-202.	2.5	29
416	Application of ICHD 2nd edition criteria for primary headaches with the aid of a computerised, structured medical record for the specialist. Journal of Headache and Pain, 2005, 6, 205-210.	2.5	8
417	Acanthocytosis as a predisposing factor for non-ketotic hyperglycaemia induced chorea-ballism. Journal of Neurology, Neurosurgery and Psychiatry, 2005, 76, 1717-1719.	0.9	33
418	Pathological Synaptic Plasticity in the Striatum: Implications for Parkinson's Disease. NeuroToxicology, 2005, 26, 779-783.	1.4	80
419	Medication-overuse headache: similarities with drug addiction. Trends in Pharmacological Sciences, 2005, 26, 62-68.	4.0	138
420	Nigrostriatal Dopaminergic Deficits and Hypokinesia Caused by Inactivation of the Familial Parkinsonism-Linked Gene DJ-1. Neuron, 2005, 45, 489-496.	3.8	485
421	Modulatory action of metabotropic glutamate receptor (mGluR) 5 on mGluR1 function in striatal cholinergic interneurons. Neuropharmacology, 2005, 49, 104-113.	2.0	64
422	Long-term potentiation and memory processes in the psychological works of Sigmund Freud and in the formation of neuropsychiatric symptoms. Neuroscience, 2005, 130, 559-565.	1.1	6
423	Subthalamic nucleus lesion reverses motor abnormalities and striatal glutamatergic overactivity in experimental parkinsonism. Neuroscience, 2005, 133, 831-840.	1.1	54
424	Abnormal Sensitivity to Cannabinoid Receptor Stimulation Might Contribute to Altered Gamma-Aminobutyric Acid Transmission in the Striatum of R6/2 Huntingtonâ€™s Disease Mice. Biological Psychiatry, 2005, 57, 1583-1589.	0.7	79
425	Short and Long Term Modulation of Synaptic Activity in Striatal Cholinergic Interneurons. , 2005, , 91-97.		0
426	Engagement of Rat Striatal Neurons by Cortical Epileptiform Activity Investigated With Paired Recordings. Journal of Neurophysiology, 2004, 92, 2725-2737.	0.9	9
427	Chronic Haloperidol Promotes Corticostriatal Long-Term Potentiation by Targeting Dopamine D2L Receptors. Journal of Neuroscience, 2004, 24, 8214-8222.	1.7	90
428	Coordinate high-frequency pattern of stimulation and calcium levels control the induction of LTP in striatal cholinergic interneurons. Learning and Memory, 2004, 11, 755-760.	0.5	23
429	Coactivation of GABA A and GABA B Receptor Results in Neuroprotection During In Vitro Ischemia. Stroke, 2004, 35, 596-600.	1.0	89
430	Therapeutic doses of L-dopa reverse hypersensitivity of corticostriatal D2-dopamine receptors and glutamatergic overactivity in experimental parkinsonism. Brain, 2004, 127, 1661-1669.	3.7	78
431	A Critical Interaction between Dopamine D2 Receptors and Endocannabinoids Mediates the Effects of Cocaine on Striatal GABAergic Transmission. Neuropsychopharmacology, 2004, 29, 1488-1497.	2.8	139
432	Intracellular Calcium Increase in Epileptiform Activity: Modulation by Levetiracetam and Lamotrigine. Epilepsia, 2004, 45, 719-728.	2.6	124

#	ARTICLE	IF	CITATIONS
433	Calcium signaling and neuronal vulnerability to ischemia in the striatum. <i>Cell Calcium</i> , 2004, 36, 277-284.	1.1	32
434	Abnormal Ca ²⁺ -Calmodulin-Dependent Protein Kinase II Function Mediates Synaptic and Motor Deficits in Experimental Parkinsonism. <i>Journal of Neuroscience</i> , 2004, 24, 5283-5291.	1.7	136
435	The Project for a Scientific Psychology (1895): a Freudian anticipation of LTP-memory connection theory. <i>Brain Research Reviews</i> , 2004, 46, 310-314.	9.1	24
436	Early ionic and membrane potential changes caused by the pesticide rotenone in striatal cholinergic interneurons. <i>Experimental Neurology</i> , 2004, 185, 169-181.	2.0	20
437	Metabotropic glutamate receptors and striatal synaptic plasticity: implications for neurological diseases. <i>Progress in Neurobiology</i> , 2004, 74, 271-300.	2.8	139
438	Induction of corticostriatal LTP by 3-nitropropionic acid requires the activation of mGluR1/PKC pathway. <i>Neuropharmacology</i> , 2004, 46, 761-769.	2.0	18
439	Differential contribution of dopamine D2S and D2L receptors in the modulation of glutamate and GABA transmission in the striatum. <i>Neuroscience</i> , 2004, 129, 157-166.	1.1	77
440	Inhibition of mitochondrial complex II alters striatal expression of genes involved in glutamatergic and dopaminergic signaling: possible implications for Huntington's disease. <i>Neurobiology of Disease</i> , 2004, 15, 407-414.	2.1	24
441	Levetiracetam protects against kainic acid-induced toxicity. <i>Life Sciences</i> , 2004, 74, 1253-1264.	2.0	61
442	Neuronal vulnerability following inhibition of mitochondrial complex II: a possible ionic mechanism for Huntington's disease. <i>Molecular and Cellular Neurosciences</i> , 2004, 25, 9-20.	1.0	47
443	Phyto-oestrogens in the Prophylaxis of Menstrual Migraine. <i>Clinical Neuropharmacology</i> , 2004, 27, 137-140.	0.2	24
444	Glutamate Transmission in the Pathogenesis of Parkinson's Disease. , 2004, , 229-242.		1
445	Synaptic plasticity in the ischaemic brain. <i>Lancet Neurology</i> , The, 2003, 2, 622-629.	4.9	139
446	Antiepileptic drugs as a possible neuroprotective strategy in brain ischemia. <i>Annals of Neurology</i> , 2003, 53, 693-702.	2.8	125
447	Levodopa treatment reverses endocannabinoid system abnormalities in experimental parkinsonism. <i>Journal of Neurochemistry</i> , 2003, 85, 1018-1025.	2.1	145
448	Cyclic Vomiting Syndrome, Migraine, and Epilepsy: A Common Underlying Disorder?. <i>Headache</i> , 2003, 43, 407-409.	1.8	28
449	Behavioural learning-induced increase in spontaneous GABA _A -dependent synaptic activity in rat striatal cholinergic interneurons. <i>European Journal of Neuroscience</i> , 2003, 17, 174-178.	1.2	11
450	Voltage-dependent membrane potential oscillations of rat striatal fast-spiking interneurons. <i>Journal of Physiology</i> , 2003, 549, 121-130.	1.3	75

#	ARTICLE	IF	CITATIONS
451	Loss of bidirectional striatal synaptic plasticity in L-DOPA-induced dyskinesia. <i>Nature Neuroscience</i> , 2003, 6, 501-506.	7.1	791
452	Lamotrigine and remacemide protect striatal neurons against in vitro ischemia: an electrophysiological study. <i>Experimental Neurology</i> , 2003, 182, 461-469.	2.0	18
453	Corticostriatal LTP requires combined mGluR1 and mGluR5 activation. <i>Neuropharmacology</i> , 2003, 44, 8-16.	2.0	86
454	Targeting striatal cholinergic interneurons in Parkinson's disease: Focus on metabotropic glutamate receptors. <i>Neuropharmacology</i> , 2003, 45, 45-56.	2.0	85
455	Ionotropic glutamate receptors: still a target for neuroprotection in brain ischemia? insights from in vitro studies. <i>Neurobiology of Disease</i> , 2003, 12, 82-88.	2.1	40
456	Dopamine, Acetylcholine and Nitric Oxide Systems Interact to Induce Corticostriatal Synaptic Plasticity. <i>Reviews in the Neurosciences</i> , 2003, 14, 207-16.	1.4	110
457	Stimulus frequency, calcium levels and striatal synaptic plasticity. <i>NeuroReport</i> , 2003, 14, 419-422.	0.6	21
458	Distinct Roles of D ₁ and D ₅ Dopamine Receptors in Motor Activity and Striatal Synaptic Plasticity. <i>Journal of Neuroscience</i> , 2003, 23, 8506-8512.	1.7	213
459	Receptor Subtypes Involved in the Presynaptic and Postsynaptic Actions of Dopamine on Striatal Interneurons. <i>Journal of Neuroscience</i> , 2003, 23, 6245-6254.	1.7	209
460	Activation of Î²1-Adrenoceptors Excites Striatal Cholinergic Interneurons through a cAMP-Dependent, Protein Kinase-Independent Pathway. <i>Journal of Neuroscience</i> , 2003, 23, 5272-5282.	1.7	45
461	Striatal metabotropic glutamate receptor function following experimental parkinsonism and chronic levodopa treatment. <i>Brain</i> , 2002, 125, 2635-2645.	3.7	76
462	Tissue plasminogen activator is required for striatal post-ischemic synaptic potentiation. <i>NeuroReport</i> , 2002, 13, 115-118.	0.6	12
463	Post-ischaemic long-term synaptic potentiation in the striatum: a putative mechanism for cell type-specific vulnerability. <i>Brain</i> , 2002, 125, 844-860.	3.7	64
464	Impairment of mitochondrial metabolism differentially affects striatal neuronal subtypes. <i>NeuroReport</i> , 2002, 13, 641-644.	0.6	7
465	Experimental Parkinsonism Modulates Multiple Genes Involved in the Transduction of Dopaminergic Signals in the Striatum. <i>Neurobiology of Disease</i> , 2002, 10, 387-395.	2.1	43
466	Dopamine Excites Fast-Spiking Interneurons in the Striatum. <i>Journal of Neurophysiology</i> , 2002, 87, 2190-2194.	0.9	140
467	Endogenous Dopamine Amplifies Ischemic Long-Term Potentiation via D1 Receptors. <i>Stroke</i> , 2002, 33, 2978-2984.	1.0	27
468	Metabotropic Glutamate 2 Receptors Modulate Synaptic Inputs and Calcium Signals in Striatal Cholinergic Interneurons. <i>Journal of Neuroscience</i> , 2002, 22, 6176-6185.	1.7	67

#	ARTICLE	IF	CITATIONS
469	Experimental Parkinsonism Alters Endocannabinoid Degradation: Implications for Striatal Glutamatergic Transmission. <i>Journal of Neuroscience</i> , 2002, 22, 6900-6907.	1.7	303
470	Cocaine and Amphetamine Depress Striatal GABAergic Synaptic Transmission through D2 Dopamine Receptors. <i>Neuropsychopharmacology</i> , 2002, 26, 164-175.	2.8	78
471	Dopamine D2 Receptor-Mediated Inhibition of Dopaminergic Neurons in Mice Lacking D2L Receptors. <i>Neuropsychopharmacology</i> , 2002, 27, 723-726.	2.8	79
472	Adrenomyeloneuropathy partially responsive to steroid pulse therapy. <i>Neurological Sciences</i> , 2002, 23, 141-142.	0.9	3
473	Activation of dopamine D1-like receptors excites LTS interneurons of the striatum. <i>European Journal of Neuroscience</i> , 2002, 15, 2049-2052.	1.2	69
474	Tissue plasminogen activator is required for corticostriatal long-term potentiation. <i>European Journal of Neuroscience</i> , 2002, 16, 713-721.	1.2	52
475	Mutant huntingtin goes straight to the heart. <i>Nature Neuroscience</i> , 2002, 5, 711-712.	7.1	15
476	Dopamine-Dependent Long-Term Potentiation Induced by 3-Nitropropionic Acid in Striatal Medium Spiny Neurons. <i>Advances in Behavioral Biology</i> , 2002, , 187-190.	0.2	0
477	Cellular Actions of Dopamine. <i>Handbook of Experimental Pharmacology</i> , 2002, , 299-319.	0.9	0
478	Impaired Excitatory Transmission in the Striatum of Rats Chronically Intoxicated with Manganese. <i>Experimental Neurology</i> , 2001, 172, 469-476.	2.0	29
479	Selective Blockade of Type-1 Metabotropic Glutamate Receptors Induces Neuroprotection by Enhancing Gabaergic Transmission. <i>Molecular and Cellular Neurosciences</i> , 2001, 17, 1071-1083.	1.0	92
480	A Synaptic Mechanism Underlying the Behavioral Abnormalities Induced by Manganese Intoxication. <i>Neurobiology of Disease</i> , 2001, 8, 419-432.	2.1	72
481	Metabotropic glutamate receptor 5 mediates the potentiation of N-methyl-D-aspartate responses in medium spiny striatal neurons. <i>Neuroscience</i> , 2001, 106, 579-587.	1.1	292
482	Ionic mechanisms underlying differential vulnerability to ischemia in striatal neurons. <i>Progress in Neurobiology</i> , 2001, 63, 687-696.	2.8	59
483	Functional coexpression of excitatory mGluR1 and mGluR5 on striatal cholinergic interneurons. <i>Neuropharmacology</i> , 2001, 40, 460-463.	2.0	55
484	Selective involvement of mGlu1 receptors in corticostriatal LTD. <i>Neuropharmacology</i> , 2001, 40, 839-846.	2.0	104
485	Inhibition of Mitochondrial Complex II Induces a Long-Term Potentiation of NMDA-Mediated Synaptic Excitation in the Striatum Requiring Endogenous Dopamine. <i>Journal of Neuroscience</i> , 2001, 21, 5110-5120.	1.7	152
486	Stimulation of Nitric Oxide-cGMP Pathway Excites Striatal Cholinergic Interneurons via Protein Kinase G Activation. <i>Journal of Neuroscience</i> , 2001, 21, 1393-1400.	1.7	44

#	ARTICLE	IF	CITATIONS
487	An abnormal striatal synaptic plasticity may account for the selective neuronal vulnerability in Huntington's disease. <i>Neurological Sciences</i> , 2001, 22, 61-62.	0.9	14
488	Dopaminergic control of synaptic plasticity in the dorsal striatum. <i>European Journal of Neuroscience</i> , 2001, 13, 1071-1077.	1.2	319
489	Adenosine-mediated inhibition of striatal GABAergic synaptic transmission during in vitro ischaemia. <i>Brain</i> , 2001, 124, 1855-1865.	3.7	38
490	Activation of metabotropic glutamate receptor subtype 1/protein kinase C/mitogen-activated protein kinase pathway is required for posts ischemic long-term potentiation in the striatum. <i>Molecular Pharmacology</i> , 2001, 60, 808-15.	1.0	32
491	Tissue plasminogen activator controls multiple forms of synaptic plasticity and memory. <i>European Journal of Neuroscience</i> , 2000, 12, 1002-1012.	1.2	158
492	Involvement of Intracellular Calcium Stores during Oxygen/Glucose Deprivation in Striatal Large Aspiny Interneurons. <i>Journal of Cerebral Blood Flow and Metabolism</i> , 2000, 20, 839-846.	2.4	28
493	Cell-type specificity of mGluR activation in striatal neuronal subtypes. <i>Amino Acids</i> , 2000, 19, 119-129.	1.2	28
494	Dopamine and cAMP-Regulated Phosphoprotein 32 kDa Controls Both Striatal Long-Term Depression and Long-Term Potentiation, Opposing Forms of Synaptic Plasticity. <i>Journal of Neuroscience</i> , 2000, 20, 8443-8451.	1.7	337
495	Activation of D2-Like Dopamine Receptors Reduces Synaptic Inputs to Striatal Cholinergic Interneurons. <i>Journal of Neuroscience</i> , 2000, 20, RC69-RC69.	1.7	144
496	Is Pharmacological Neuroprotection Dependent on Reduced Glutamate Release?. <i>Stroke</i> , 2000, 31, 766-773.	1.0	71
497	Cellular factors controlling neuronal vulnerability in the brain. <i>Neurology</i> , 2000, 55, 1249-1255.	1.5	111
498	Electrophysiology of Sipatrigine: A Lamotrigine Derivative Exhibiting Neuroprotective Effects. <i>Experimental Neurology</i> , 2000, 162, 171-179.	2.0	11
499	Acetylcholine-mediated modulation of striatal function. <i>Trends in Neurosciences</i> , 2000, 23, 120-126.	4.2	400
500	Synaptic transmission in the striatum: from plasticity to neurodegeneration. <i>Progress in Neurobiology</i> , 2000, 61, 231-265.	2.8	254
501	Electrophysiology of dopamine in normal and denervated striatal neurons. <i>Trends in Neurosciences</i> , 2000, 23, S57-S63.	4.2	145
502	Sipatrigine (BW 619C89) is a Neuroprotective Agent and a Sodium Channel and Calcium Channel Inhibitor. <i>CNS Neuroscience & Therapeutics</i> , 2000, 6, 111-134.	4.0	23
503	Levodopa-induced dyskinesia: a pathological form of striatal synaptic plasticity?. <i>Annals of Neurology</i> , 2000, 47, S60-8; discussion S68-9.	2.8	79
504	Glutamate-Triggered Events Inducing Corticostriatal Long-Term Depression. <i>Journal of Neuroscience</i> , 1999, 19, 6102-6110.	1.7	87

#	ARTICLE	IF	CITATIONS
505	A Critical Role of the Nitric Oxide/cGMP Pathway in Corticostriatal Long-Term Depression. <i>Journal of Neuroscience</i> , 1999, 19, 2489-2499.	1.7	218
506	Unilateral Dopamine Denervation Blocks Corticostriatal LTP. <i>Journal of Neurophysiology</i> , 1999, 82, 3575-3579.	0.9	214
507	Electrophysiological Recordings and Calcium Measurements in Striatal Large Aspiny Interneurons in Response to Combined O ₂ /Glucose Deprivation. <i>Journal of Neurophysiology</i> , 1999, 81, 2508-2516.	0.9	46
508	An in vitro electrophysiological study on the effects of phenytoin, lamotrigine and gabapentin on striatal neurons. <i>British Journal of Pharmacology</i> , 1999, 126, 689-696.	2.7	65
509	Permissive role of interneurons in corticostriatal synaptic plasticity. <i>Brain Research Reviews</i> , 1999, 31, 1-5.	9.1	86
510	Modulation of gene expression following long-term synaptic depression in the striatum. <i>Molecular Brain Research</i> , 1999, 72, 89-96.	2.5	26
511	Activation of M1-like muscarinic receptors is required for the induction of corticostriatal LTP. <i>Neuropharmacology</i> , 1999, 38, 323-326.	2.0	118
512	Neurophysiology of Parkinson's disease: from basic research to clinical correlates. <i>Clinical Neurophysiology</i> , 1999, 110, 2006-2013.	0.7	17
513	Metabotropic Glutamate Receptors and Cell-Type-Specific Vulnerability in the Striatum: Implication for Ischemia and Huntington's Disease. <i>Experimental Neurology</i> , 1999, 158, 97-108.	2.0	99
514	Sodium Influx Plays a Major Role in the Membrane Depolarization Induced by Oxygen and Glucose Deprivation in Rat Striatal Spiny Neurons. <i>Stroke</i> , 1999, 30, 171-179.	1.0	70
515	Pharmacological Inhibition of the Na ⁺ /Ca ²⁺ Exchanger Enhances Depolarizations Induced by Oxygen/Glucose Deprivation but Not Responses to Excitatory Amino Acids in Rat Striatal Neurons. <i>Stroke</i> , 1999, 30, 1687-1694.	1.0	23
516	Muscarinic IPSPs in rat striatal cholinergic interneurons. <i>Journal of Physiology</i> , 1998, 510, 421-427.	1.3	83
517	Endogenous ACh enhances striatal NMDA-responses via M1-like muscarinic receptors and PKC activation. <i>European Journal of Neuroscience</i> , 1998, 10, 2887-2895.	1.2	133
518	Hypoglycemia, Hypoxia, and Ischemia in a Corticostriatal Slice Preparation: Electrophysiologic Changes and Ascorbyl Radical Formation. <i>Journal of Cerebral Blood Flow and Metabolism</i> , 1998, 18, 868-875.	2.4	19
519	Blockade of M2-like muscarinic receptors enhances long-term potentiation at corticostriatal synapses. <i>European Journal of Neuroscience</i> , 1998, 10, 3020-3023.	1.2	89
520	Striatal spiny neurons and cholinergic interneurons express differential ionotropic glutamatergic responses and vulnerability: Implications for ischemia and Huntington's disease. <i>Annals of Neurology</i> , 1998, 43, 586-597.	2.8	126
521	Morphological and functional study of dwarf neurons in the rat striatum. <i>European Journal of Neuroscience</i> , 1998, 10, 3575-3583.	1.2	7
522	SHORT COMUNICATION Early sodium elevations induced by combined oxygen and glucose deprivation in pyramidal cortical neurons. <i>European Journal of Neuroscience</i> , 1998, 10, 3572-3574.	1.2	25

#	ARTICLE	IF	CITATIONS
523	Electrophysiology of the neuroprotective agent riluzole on striatal spiny neurons. <i>Neuropharmacology</i> , 1998, 37, 1063-1070.	2.0	39
524	L-Type Ca ²⁺ Channel Blockers Attenuate Electrical Changes and Ca ²⁺ Rise Induced by Oxygen/Glucose Deprivation in Cortical Neurons. <i>Stroke</i> , 1998, 29, 196-202.	1.0	67
525	Hypoxic and hypoglycaemic changes of intracellular pH in cerebral cortical pyramidal neurones. <i>NeuroReport</i> , 1998, 9, 1447-1450.	0.6	8
526	Prolactin Response to Bromocriptine in Flunarizine-Treated Migrainous Women. <i>Clinical Neuropharmacology</i> , 1997, 20, 234-238.	0.2	2
527	Hypoxia in striatal and cortical neurones. <i>NeuroReport</i> , 1997, 8, 1143-1147.	0.6	15
528	Activation of Group III Metabotropic Glutamate Receptors Depresses Glutamatergic Transmission at Corticostriatal Synapse. <i>Neuropharmacology</i> , 1997, 36, 845-851.	2.0	99
529	Discussion. <i>Neuroscience</i> , 1997, 78, 39-60.	1.1	139
530	Correspondence. <i>Neuroscience</i> , 1997, 79, 323-327.	1.1	190
531	Epileptiform discharge induced by 4-aminopyridine in magnesium-free medium in neocortical neurons: physiological and pharmacological characterization. <i>Neuroscience</i> , 1997, 81, 189-197.	1.1	40
532	Opposite Membrane Potential Changes Induced by Glucose Deprivation in Striatal Spiny Neurons and in Large Aspiny Interneurons. <i>Journal of Neuroscience</i> , 1997, 17, 1940-1949.	1.7	65
533	Endogenous Adenosine Mediates the Presynaptic Inhibition Induced by Aglycemia at Corticostriatal Synapses. <i>Journal of Neuroscience</i> , 1997, 17, 4509-4516.	1.7	67
534	Abnormal Synaptic Plasticity in the Striatum of Mice Lacking Dopamine D2 Receptors. <i>Journal of Neuroscience</i> , 1997, 17, 4536-4544.	1.7	279
535	A Possible Mechanism for the Aglycemia-Induced Depression of Glutamatergic Excitation in the Striatum. <i>Journal of Cerebral Blood Flow and Metabolism</i> , 1997, 17, 1121-1126.	2.4	14
536	Enhancement of NMDA responses by group I metabotropic glutamate receptor activation in striatal neurones. <i>British Journal of Pharmacology</i> , 1997, 120, 1007-1014.	2.7	193
537	Synaptic plasticity and physiological interactions between dopamine and glutamate in the striatum. <i>Neuroscience and Biobehavioral Reviews</i> , 1997, 21, 519-523.	2.9	96
538	Electrophysiological effects of monoamine oxidase inhibition on rat midbrain dopaminergic neurones: an <i>in vitro</i> study. <i>British Journal of Pharmacology</i> , 1996, 117, 528-532.	2.7	15
539	The corticostriatal projection: from synaptic plasticity to dysfunctions of the basal ganglia. <i>Trends in Neurosciences</i> , 1996, 19, 19-24.	4.2	420
540	Long-term changes of synaptic transmission: A topic of long-term interest. <i>Behavioral and Brain Sciences</i> , 1996, 19, 439-440.	0.4	2

#	ARTICLE	IF	CITATIONS
541	The modulation of calcium currents by the activation of mGluRs. <i>Molecular Neurobiology</i> , 1996, 13, 81-95.	1.9	54
542	Role of Ca ²⁺ in striatal LTD and LTP. <i>Seminars in Neuroscience</i> , 1996, 8, 321-328.	2.3	28
543	Characterization of a Barium-sensitive Outward Current following Glutamate Application on Rat Midbrain Dopaminergic Cells. <i>European Journal of Neuroscience</i> , 1996, 8, 1780-1786.	1.2	8
544	A field potential analysis on the effects of lamotrigine, GP 47779, and felbamate in neocortical slices. <i>Neurology</i> , 1996, 47, 557-562.	1.5	35
545	Action of GP 47779, the Active Metabolite of Oxcarbazepine, on the Corticostriatal System. I. Modulation of Corticostriatal Synaptic Transmission. <i>Epilepsia</i> , 1995, 36, 990-996.	2.6	51
546	Action of GP 47779, the Active Metabolite of Oxcarbazepine, on the Corticostriatal System. II. Modulation of High-Voltage-Activated Calcium Currents. <i>Epilepsia</i> , 1995, 36, 997-1002.	2.6	101
547	Sex-Hormone-Related Events in Migrainous Females. A Clinical Comparative Study Between Migraine With Aura and Migraine Without Aura. <i>Cephalalgia</i> , 1995, 15, 140-144.	1.8	153
548	Hypoxia-Induced Electrical Changes in Striatal Neurons. <i>Journal of Cerebral Blood Flow and Metabolism</i> , 1995, 15, 1141-1145.	2.4	17
549	Properties of the Hyperpolarization-activated Cation Current I _h in Rat Midbrain Dopaminergic Neurons. <i>European Journal of Neuroscience</i> , 1995, 7, 462-469.	1.2	190
550	Actions of Glycine on Non-dopaminergic Neurons of the Rat Substantia Nigra. <i>European Journal of Neuroscience</i> , 1995, 7, 2351-2354.	1.2	5
551	Vulnerability of Medium Spiny Striatal Neurons to Glutamate: Role of Na ⁺ /K ⁺ ATPase. <i>European Journal of Neuroscience</i> , 1995, 7, 1674-1683.	1.2	78
552	Transmitter Release Associated with Long-term Synaptic Depression in Rat Corticostriatal Slices. <i>European Journal of Neuroscience</i> , 1995, 7, 1889-1894.	1.2	37
553	On the mechanisms underlying hypoxia-induced membrane depolarization in striatal neurons. <i>Brain</i> , 1995, 118, 1027-1038.	3.7	89
554	Electrophysiology of dopamine D-1 receptors in the basal ganglia: Old facts and new perspectives. <i>Progress in Neuro-Psychopharmacology and Biological Psychiatry</i> , 1995, 19, 779-793.	2.5	5
555	Electrophysiological actions of felbamate on rat striatal neurones. <i>British Journal of Pharmacology</i> , 1995, 116, 2053-2061.	2.7	45
556	Long-Term Changes of Corticostriatal Synaptic Transmission: Possible Implication for Motor Memory. <i>Neuroscience</i> , 1995, 68, 89-103.		3
557	Effects of anoxia on rat midbrain dopamine neurons. <i>Journal of Neurophysiology</i> , 1994, 71, 1165-1173.	0.9	48
558	Post-receptor mechanisms underlying striatal long-term depression. <i>Journal of Neuroscience</i> , 1994, 14, 4871-4881.	1.7	209

#	ARTICLE	IF	CITATIONS
559	Activation of metabotropic glutamate receptors inhibits calcium currents and GABA-mediated synaptic potentials in striatal neurons. <i>Journal of Neuroscience</i> , 1994, 14, 6734-6743.	1.7	95
560	Responses of rat mesencephalic dopaminergic neurons to a prolonged period of oxygen deprivation. <i>Neuroscience</i> , 1994, 63, 757-764.	1.1	20
561	Effects of dihydropyridine calcium antagonists on rat midbrain dopaminergic neurones. <i>British Journal of Pharmacology</i> , 1994, 113, 831-838.	2.7	133
562	Basic Electrophysiology and Possible New Therapeutic Approaches to Movement Disorders. <i>Advances in Behavioral Biology</i> , 1994, , 229-237.	0.2	1
563	1-Deprenyl Test in Migraine: Neuroendocrinological Aspects. <i>Cephalgia</i> , 1993, 13, 406-409.	1.8	16
564	Heterogeneity of Metabotropic Glutamate Receptors in the Striatum: Electrophysiological Evidence. <i>European Journal of Neuroscience</i> , 1993, 5, 1370-1377.	1.2	66
565	Activation of metabotropic glutamate receptors induces an inward current in rat dopamine mesencephalic neurons. <i>Neuroscience</i> , 1993, 56, 399-407.	1.1	69
566	Lithium Treatment Blocks Long-Term Synaptic Depression in the Striatum. <i>Neuron</i> , 1993, 10, 955-962.	3.8	43
567	Neurotensin induces an inward current in rat mesencephalic dopaminergic neurons. <i>Neuroscience Letters</i> , 1993, 153, 192-196.	1.0	39
568	Chapter 19 Chemical modulation of synaptic transmission in the striatum. <i>Progress in Brain Research</i> , 1993, 99, 299-308.	0.9	18
569	Electrophysiology of dopamine-denervated striatal neurons. Implications for Parkinson's disease. <i>Brain</i> , 1993, 116 (Pt 2), 433-52.	3.7	76
570	The electrophysiological actions of dopamine and dopaminergic drugs on neurons of the substantia nigra pars compacta and ventral tegmental area. <i>Life Sciences</i> , 1992, 51, 711-718.	2.0	74
571	Coactivation of D1 and D2 dopamine receptors is required for long-term synaptic depression in the striatum. <i>Neuroscience Letters</i> , 1992, 142, 95-99.	1.0	186
572	A-current in rat globus pallidus: A whole-cell voltage clamp study on acutely dissociated neurons. <i>Neuroscience Letters</i> , 1992, 144, 4-8.	1.0	14
573	Activation of quisqualate metabotropic receptors reduces glutamate and GABA-mediated synaptic potentials in the rat striatum. <i>Neuroscience Letters</i> , 1992, 139, 41-44.	1.0	92
574	A voltage-clamp analysis of NMDA-induced responses on dopaminergic neurons of the rat substantia nigra zona compacta and ventral tegmental area. <i>Brain Research</i> , 1992, 593, 51-56.	1.1	34
575	Long-term synaptic depression in the striatum: physiological and pharmacological characterization. <i>Journal of Neuroscience</i> , 1992, 12, 4224-4233.	1.7	639
576	Migraine with Aura-Like Syndrome Due to Arteriovenous Malformation. The Clinical Value of Transcranial Doppler in Early Diagnosis. <i>Cephalgia</i> , 1992, 12, 115-119.	1.8	15

#	ARTICLE	IF	CITATIONS
577	Long-term Potentiation in the Striatum is Unmasked by Removing the Voltage-dependent Magnesium Block of NMDA Receptor Channels. <i>European Journal of Neuroscience</i> , 1992, 4, 929-935.	1.2	380
578	Chronic neuroleptic treatment: D2 dopamine receptor supersensitivity and striatal glutamatergic transmission. <i>Annals of Neurology</i> , 1992, 31, 366-373.	2.8	78
579	Electrophysiological effects of amineptine on neurones of the rat substantia nigra pars compacta: evidence for an inhibition of the dopamine uptake system. <i>British Journal of Pharmacology</i> , 1991, 104, 700-704.	2.7	12
580	Nomifensine but not amantadine increases dopamine-induced responses on rat substantia nigra zona compacta neurons. <i>Neuroscience Letters</i> , 1991, 131, 145-148.	1.0	13
581	Dopamine uptake inhibition potentiates the effects of L-DOPA on rat substantia nigra zona compacta neurons. <i>Neuroscience Letters</i> , 1991, 126, 79-82.	1.0	11
582	Involvement of GABA systems in feedback regulation of glutamate-and GABA-mediated synaptic potentials in rat neostriatum.. <i>Journal of Physiology</i> , 1991, 440, 581-599.	1.3	119
583	GABA depolarizes neurons in the rat striatum: An in vivo study. <i>Synapse</i> , 1991, 8, 38-40.	0.6	33
584	Effects of glycine on neurons in the rat substantia nigra zona compacta: In vitro electrophysiological study. <i>Synapse</i> , 1990, 5, 190-200.	0.6	18
585	Synaptic and intrinsic control of membrane excitability of neostriatal neurons. II. An in vitro analysis. <i>Journal of Neurophysiology</i> , 1990, 63, 663-675.	0.9	96
586	Synaptic and intrinsic control of membrane excitability of neostriatal neurons. I. An in vivo analysis. <i>Journal of Neurophysiology</i> , 1990, 63, 651-662.	0.9	122
587	Kainic acid on neostriatal neurons intracellularly recorded in vitro: electrophysiological evidence for differential neuronal sensitivity. <i>Journal of Neuroscience</i> , 1990, 10, 3960-3969.	1.7	28
588	Endogenous GABA mediates presynaptic inhibition of spontaneous and evoked excitatory synaptic potentials in the rat neostriatum. <i>Neuroscience Letters</i> , 1990, 118, 99-102.	1.0	50
589	Responses of rat substantia nigra compacta neurones to L-DOPA. <i>British Journal of Pharmacology</i> , 1990, 100, 257-260.	2.7	48
590	Muscarine depolarizes rat substantia nigra zona compacta and ventral tegmental neurons in vitro through M1-like receptors. <i>Journal of Pharmacology and Experimental Therapeutics</i> , 1990, 253, 395-400.	1.3	105
591	Selective depression of synaptic transmission by tetanus toxin: A comparative study on hippocampal and neostriatal slices. <i>Neuroscience</i> , 1989, 30, 663-670.	1.1	36
592	The mechanism of amphetamine-induced inhibition of rat substantia nigra compacta neurones investigated with intracellular recording <i>in vitro</i> . <i>British Journal of Pharmacology</i> , 1989, 98, 127-134.	2.7	45
593	Nicotinic excitation of rat ventral tegmental neurones <i>in vitro</i> studied by intracellular recording. <i>British Journal of Pharmacology</i> , 1989, 98, 135-140.	2.7	253
594	Physiology and pharmacology of dopamine D ₂ receptors. <i>Neurology</i> , 1989, 39, 1106-1106.	1.5	14

#	ARTICLE	IF	CITATIONS
595	Potassium ions play a role in the glycine-induced inhibition of rat substantia nigra zona compacta neurones. <i>Brain Research</i> , 1988, 462, 199-203.	1.1	16
596	Depletion of catecholamines reveals inhibitory effects of bromocryptine and lysuride on neostriatal neurones recorded intracellularly in vitro. <i>Neuropharmacology</i> , 1988, 27, 579-587.	2.0	19
597	Endogenous dopamine and dopaminergic agonists modulate synaptic excitation in neostriatum: Intracellular studies from naive and catecholamine-depleted rats. <i>Neuroscience</i> , 1988, 27, 145-157.	1.1	62
598	Intracellular studies on the dopamine-induced firing inhibition of neostriatal neurons in vitro: Evidence for D1 receptor involvement. <i>Neuroscience</i> , 1987, 20, 757-771.	1.1	261
599	Intrinsic membrane properties of neostriatal neurons can account for their low level of spontaneous activity. <i>Neuroscience</i> , 1987, 20, 293-303.	1.1	106
600	Muscarinic modulation of calcium dependent plateau potentials in rat neostriatal neurons. <i>Pflugers Archiv European Journal of Physiology</i> , 1986, 407, 482-487.	1.3	53
601	Dopamine decreases cell excitability in rat striatal neurons by pre- and postsynaptic mechanisms. <i>Brain Research</i> , 1985, 358, 110-121.	1.1	92
602	Dopamine modulates CA1 hippocampal neurons by elevating the threshold for spike generation: An in vitro study. <i>Neuroscience</i> , 1984, 13, 1105-1116.	1.1	72